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Improved therapies for cancer and other conditions have resulted in a growing population of 
long-term survivors. Infertility is an unfortunate side effect of some cancer therapies that impacts 
the quality of life of survivors who are in their reproductive or pre-reproductive years. Some of 
these patients have the opportunity to preserve their fertility using standard technologies that 
include sperm, egg or embryo banking, followed by in vitro fertilization and/or embryo transfer.  
However, these options are not available to all patients, especially the prepubertal patients who 
are not yet producing mature gametes. For these patients, there are several stem cell technologies 
in the research pipeline that may give rise to new fertility options and allow infertile patients to 
have their own biological children. Spermatogonial stem cells are the foundation of 
spermatogenesis and may have application for preserving and restoring male fertility. However, 
majority of the knowledge about spermatogonial stem cells (SSCs) comes from rodents and not 
much is known about humans. In Chapter 2, I demonstrate that human spermatogonia have the 
phenotype of UTF1+, SALL4+, ENO2+, UCHL1+, ZBTB16+, ITGA6+, THY1dim, EPCAMdim, 
KIT- and that using the cell surface markers ITGA6, THY1, EPCAM it is possible to enrich 
human SSCs. In Chapter 3, I used this knowledge about the phenotype of human spermatogonia 
to show that the best method to cryopreserve intact human testicular pieces is controlled slow-
freezing. In Chapter 4, I used the phenotype of human spermatogonia from Chapter 2, to show 
that it is possible to separate potentially therapeutic human spermatogonial stem cells from 
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malignant contamination. This is important because a majority of our prepubertal patients will 
have a testicular biopsy taken prior to initiation of chemotherapy so we want to make sure there 
would be no malignant contamination in the sample. Progress represented by this thesis research 
will facilitate translating SSC technologies toward the clinic for preservation and restoration of 
male fertility.  
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1.0  INTRODUCTION 
Spermatogenesis is a highly organized process that produces millions of sperm each day in 
postpubertal mammals [1-3].  This productivity is dependent on the activity of spermatogonial 
stem cells (SSCs), which are the adult tissue stem cells in the testes that balance self-renewing 
divisions with differentiating divisions that maintain the stem cell pool and fuel spermatogenesis, 
respectively [4, 5]. When SSCs differentiate, they give rise to spermatogonia that undergo a 
species-specific number of transit amplifying mitotic divisions, followed by two meiotic 
divisions and spermiogenesis to produce terminally differentiated sperm (Figure 1A). SSCs 
reside in a specialized niche located on the basement membrane of the seminiferous tubules 
where they are in direct contact with Sertoli cells, which produce some of the paracrine factors 
required to regulate self-renewal and differentiation fate decisions (Figure 1B and C). Stem, 
progenitor and differentiating spermatogonia are all located on the basement membrane of the 
seminiferous tubules (Figure 1C). Differentiating spermatogonia give rise to spermatocytes that 
initiate meiosis and migrate off the basement membrane and produce spermatids and then sperm 
(Figure 1C). 
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Figure 1. Mammalian Spermatogenesis.  
 (A) The pool of diploid (2N) spermatogonial stem cells (SSCs) balance self-renewing and differentiating 
divisions to maintain the stem cell pool and also continuously produce sperm. Once committed to differentiate, 
SSCs give rise to undifferentiated and differentiating spermatogonia (2N), which undergo a species dependent 
number of transit-amplifying mitotic divisions that can dramatically increase the yield of sperm from a single 
stem cell. Differentiating spermatogonia give rise to primary spermatocytes (4N), which undergo two meiotic 
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1.1 SPERMATOGONIAL STEM CELLS AND SPERMATOGENESIS 
The majority of the knowledge about SSCs comes from rodents, where the SSC pool is 
considered to reside in the population of isolated type Asingle (As) spermatogonia. In the rodent 
testis, As spermatogonia are rare, comprising 0.03% of all germ cells in the mouse testis [5]; they 
are evenly distributed along the basement membrane of seminiferous tubules, have a relatively 
large nuclear to cytoplasmic ratio and diffuse chromatin. When As spermatogonia divide, they 
produce Apair (Apr) spermatogonia that either undergo complete cytokinesis to produce two new 
As (self-renew) or remain connected by an intercytoplasmic bridge to produce a chain of four 
Aaligned (Aal4) spermatogonia (Figure 2B). Thus, at least a portion of Apr must function as stem 
cells because they contribute to self-renewal of the As pool. Successive divisions of Aal4 produce 
chains of 8, 16 and sometimes 32 Aal spermatogonia. The synchronized development of 
spermatogonial clones is facilitated by protein and messenger RNA exchange via the 
intercytoplasmic bridges that connect the individual cells within a chain [6]. Types As, Apr and 
Aal spermatogonia are collectively termed Aundifferentiated (Aundiff) spermatogonia (Figure 2A and 
B). In rodents, undifferentiated spermatogonia give rise to differentiating types A1, A2, A3, A4, 
divisions to produce haploid spermatids (1N). The meiotic divisions are followed by spermiogenesis to produce 
terminally differentaited sperm. (B) Spermatogenesis takes place inside the seminiferous tubules of the testis. (C) 
Cut out of the seminiferous epithelium. Spermatogonia (including SSCs) located on the basement membrane of 
seminiferous tubules give rise to primary spermatocytes, which initiate meiosis and migrate off the basement 
membrane. Two meiotic divisions and spermiogenesis give rise sequentially to secondary spermatocytes, 
spermatids and terminally differentiated sperm, which are released into the lumen of the seminiferous tubule. 
Reprinted from Valli et al., Fertil Steril. 2014 Jan;101(1):3-13, Copyright (2014), with permission from Elsevier 
Ltd. 
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Intermediate and B spermatogonia, followed by primary spermatocytes, secondary 
spermatocytes, spermatids and sperm.  
Depending on whether the transition from Aal to differentiating A1 spermatogonia occurs 
from Aal chains of 4, 8, 16 or 32 spermatogonia, a clone generated from a single SSC can 
theoretically give rise to between 1024 and 8192 sperm in rodents [7, 8]. The actual yield of 
sperm is 50-80% less than what would be predicted by the clonal amplification scheme described 
above and this is due to apoptosis that occurs primarily in the A2-A4 spermatogonia in rodents 
[9-12].  
In rodents, no SSC specific marker has been identified but several markers have been 
described that are expressed by stem and/or progenitor cells (e.g. GFRα1, POU3F1, POU5F1 
(OCT4), ZBTB16 (PLZF), NGN3, NANOS2, NANOS3, SOHLH1, SOHLH2, FOXO1, ITGA6 
(α6-integrin, CD49f), LIN28, ID4, PAX7, UTF1, CDH1, GPR125, ITGB1 (β1-integrin, CD29), 
EPCAM (CD326), CD9 and THY1 (CD90) [13-43]). When the spermatogonia go through 
differentiation, expression of stem and progenitor markers is reduced and expression of 
differentiation markers (e.g., NGN3 and KIT) increases (Figure 2B). When coupled with whole 
mount immunofluorescence, clonal arrangement of spermatogonia can be determined (Figure 2A 
and B).  
In contrast to rodents, undifferentiated (Type A) spermatogonia in primates are termed  
Adark and Apale, based on differences in nuclear architecture and staining with hematoxylin in 
histological sections (Figure 2E) [44-48]. Adark and Apale are both found on the basement 
membrane of primate seminiferous tubules, but in contrast to rodents (Figure 2A and B) there are 
limited data describing their molecular characteristics or clonal arrangement [46, 48, 49] and 
conflicting views on whether one or both populations function as active stem cells in steady state 
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spermatogenesis [7, 48, 50-53]. This is an important knowledge deficit because spermatogonial 
stem cells may have application for treating male infertility.  
 
 
Figure 2. Current model of rodent, nonhuman primate and human spermatogenesis.  
  
 
 
 
 
 
 
 
 
 (A) Whole-mount immunohistochemistry staining for ZBTB16 in adult mouse seminiferous tubules. ZBTB16+ 
spermatogonia are identified as Asingle, Apaired or Aaligned. Scale bar = 100µm. (B) Rodent undifferentiated 
spermatogonia, including the SSC pool, is comprised of  Asingle and some Apaired spermatogonia and based on 
whole-mount staining analysis their phenotype is of GFRα1+, ZBTB16+, SALL4+, UTF1+, NGN3+/-and KIT-. 
Transit amplifying progenitors include some Apaired spermatogonia and Aaligned spermatogonia (chains of 4-16 
cells), with a phenotype of GFRα1+, ZBTB16+, SALL4+, UTF1+, NGN3+/- and KIT+/-. The differentiating 
spermatogonia that are made up of A1-A4, Intermediate and B spermatognia, have a phenotype of GFRα1-, 
ZBTB16-, SALL4-, UTF1-, NGN3+/- and KIT+. (C and D) In nonhuman primate and human testis, the 
undifferentiated spermatogonia are the Type-A spermatogonia that are designated Adark and Apale based on nuclear 
staining intensity with hematoxylin. The B spermatogonia are considered to be the differentiating 
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1.2 MALE INFERTILITY AFTER CANCER 
High dose chemotherapy, whole body radiation or radiation to the gonads can cause permanent 
infertility [54]. This is a significant human health concern because over 75,000 people under the 
age of 40 in the United States are diagnosed with cancer each year and most are cured [55].  
Thus, cancer patients can look beyond their diagnosis and treatment to quality of life after 
cancer. Parenthood is important to cancer survivors and distress over infertility can have long-
term psychological and relationship implications [56]. Therefore, the American Society for 
Clinical Oncology (ASCO) [57] and the American Society for Reproductive Medicine (ASRM) 
Ethics Committee [58] recommend that the reproductive risks of gonadotoxic therapies and 
options for preserving fertility be discussed with patients before initiating treatment. While 
adoption and third-party reproduction provide alternative family building options, the available 
data indicate that most cancer survivors prefer to have their own biological children [57].  
Post-pubertal adolescent and adult males have the option to cryopreserve sperm prior to 
oncologic treatment. This is a simple and established method for preserving fertile potential and 
spermatogonia and in nonhuman primates they go through 4 divisons before producing primary spermatocytes, 
whereas in human there is only one division of B spermatogonia. (E) Sections of human testis stained using 
Periodic Acid-Shiff method and counterstained with hematoxylin to show nuclear morphology. Abbreviations: 
ZBTB16, zinc finger and BTB domain containing 16; GFRα1, GDNF family receptor alpha-1; UTF1, 
undifferentiated embryonic cell transcription factor 1; SALL4, Sal-like 4; NGN3, neurogenin 3; SOHLH1, 
spermatogenesis and oogenesis specific helix-loop-helix 1. Reprinted with permission from Valli, H. et al., (in 
publication) Chapter 15: Spermatogonial Stem Cells and Spermatogenesis. In Plant TM and Zeleznik AJ, Knobil 
and Neill's Physiology of Reproduction. 
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allows men to father their own genetic children. Nearly 17,000 men between the ages of 15 and 
44 are diagnosed with cancer each year in the United States and nearly 2385 survivors will 
receive a treatment that puts them at high risk of azoospermia [55, 59]. Unfortunately, only about 
24% of men in this age range cryopreserved semen prior to their oncologic treatment [60]. 
Therefore, I calculate that each year in the United States, over 1800 adult cancer survivors will 
be infertile with azoospermia and have limited options to have their own biological children 
because they did not save a semen sample. In some cases, sperm can be recovered surgically 
from small focal areas of spermatogenesis in the testes using the testicular sperm extraction 
(TESE) method and used to fertilize oocytes by intracytoplasmic sperm injection (ICSI) [61]. 
There are no options to preserve the fertility of prepubertal boys, who are not yet making 
sperm. This is a significant problem because about 5131 boys under the age of 15 in the United 
States are expected to develop cancer each year and 83% are expected to survive [55]. A report 
from the Childhood Cancer Survivor Study indicates that the cytotoxic therapies for cancer 
reduce the number subsequently able to have children by 44% [59, 62]. Based on these statistics, 
I calculate that each year in the United States, 1874 young male cancer patients will become 
sterile due to their treatment. In addition to cancer survivors, over 500 patients under the age of 
20 receive hematopoietic stem cell (HSC) transplants each year in the United States for non-
malignant conditions (e.g., bone marrow failure, blood and immune deficiencies, autoimmune 
disorders) [63]. Myeloablative conditioning therapy prior to bone marrow transplantation is 
associated with a high risk of infertility [57, 62, 64, 65]. The ASCO report notes that “Impaired 
future fertility is difficult for children to understand, but potentially traumatic to them as adults” 
[57]. The available data indicate that most parents are interested in preserving fertility on behalf 
of their children who receive gonadotoxic therapies [66, 67].   
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The summed incidence of chemotherapy or radiation-induced male infertility that cannot be 
treated with existing reproductive therapies is approximately 4000 individuals each year in the 
United States. Therefore, responsible development of novel therapies to help these patients have 
biological children has a significant potential impact.   
1.3 SPERMATOGONIAL STEM CELL TRANSPLANTATION 
Ralph Brinster pioneered the technique for spermatogonial stem cell transplantation in mice in 
1994, demonstrating that donor SSCs could engraft the seminiferous tubules of chemotherapy-
treated recipient mice and produce spermatogenesis that was competent to produce viable 
progeny [68-73]. The SSC transplantation technique has become the experimental gold standard 
for quantifying stem cell activity and may have application for treating male infertility. 
Homologous species SSC transplantation has now been reported in mice, rats, pigs, goats, bulls, 
sheep, dogs and monkeys, including the production of donor-derived progeny in mice, rats, goats 
and sheep [70, 73-86]. SSCs from donors of all ages, newborn to adult, can regenerate 
spermatogenesis [74, 87] and SSCs can be cryopreserved and retain spermatogenic function 
upon thawing and transplantation [86, 88, 89]. We recently demonstrated that prepubertal and 
adult rhesus SSCs could be frozen, thawed and transplanted to regenerate spermatogenesis and 
produce fertilization competent sperm [83, 90]. Thus, prepubertal boys or adult men should be 
able to cryopreserve testicular tissue containing SSCs prior to treatment and have these cells 
reintroduced into their testes at a later date to regenerate spermatogenesis.   
 Radford and colleagues initially introduced the autologous SSC transplantation technique 
to the human clinic in 1999 [91]. In Manchester, the United Kingdom, testicular tissue from 12 
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male non-Hodgkin’s lymphoma patients was cryopreserved as a cell suspension prior to the 
initiation of chemotherapy. At later dates, seven of the patients had the cells injected back into 
their testes [92, 93]. To our knowledge, there have been no follow up reports on the fertility 
status of those patients so the outcome of the experiment is unknown. Even if the men in that 
study fathered children, it would be difficult to demonstrate unequivocally (in the absence of a 
unique genetic marker) that those offspring resulted from sperm produced by transplanted stem 
cells rather than from surviving endogenous stem cells. There have been no other reports of SSC 
transplantation in humans since 1999. Nonetheless, this bold, pioneering study demonstrated that 
patients are willing to pursue experimental stem cell approaches to achieve fertility. To date, I 
estimate that testicular tissue or cells have been cryopreserved for more than 150 prepubertal and 
adult male patients worldwide [66, 67, 94-100]. 
 For SSC transplantation in rodents, the testes are typically accessed via a mid-ventral 
abdominal incision. Testicular cells (including SSCs) are injected using a pulled glass capillary 
pipet inserted via the efferent ducts into the rete testis space, which can be visualized on the 
surface of the testis and is contiguous with all seminiferous tubules [101] (Figure 3A-C). Testis 
anatomy in larger animals, including nonhuman primates and humans is different than rodents, 
with the rete testis being centrally located in the testes. Stefan Schlatt and colleagues [102] 
demonstrated that ultrasound can be used to visualize the rete testis and guide an injection needle 
into the rete testis space. Ultrasound-guided rete testis injection has now been employed for SSC 
transplantation in several large animals species, including nonhuman primates [76-80, 84, 85, 
90]. In contrast to the standard method in rodents, surgery is not required for ultrasound-guided 
rete testis injection. An injection needle is simply inserted under ultrasound guidance through the 
scrotal skin and testicular parenchyma into the rete testis space [90] (Figure 3D-F). Clinical 
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translation of the SSC transplantation technique appears eminent considering successes in 
several large animal models and that many patients have already cryopreserved testicular tissue 
or cells.       
 
 
 Figure 3. Testicular cell transplantation.  
 
  
 
 
 
 
 
 
 
 (A-C) In rodents, the testicular cells are injected via the efferent ducts into the rete testis space, which can be 
visualized on the surface of the testis and is contiguous with all seminiferous tubules. (C) Trypan blue is injected 
with the testicular cells to visualize the filling of the seminiferous tubules. (D-F) Testis anatomy in large animals 
is different than rodents, with the rete testis being more centrally localized and therefore more difficult to visualize 
and access. Therefore, ultrasound is used to guide injections. (D) Rete testis (echo-dense structure) is visible on 
ultrasound. The injection needle is inserted under ultrasound guidance through the scrotal skin into the rete testis 
space, which is continuous with the seminiferous tubules. (E) Positive pressure is applied to the needle so the cells 
are slowly injected into the rete testis and seminiferous tubules. (F) The filling of the seminiferous tubules is 
observed using microbubbles. Reprinted with permission from Valli, H. et al., (in publication) Chapter 15: 
Spermatogonial Stem Cells and Spermatogenesis. In Plant TM and Zeleznik AJ, Knobil and Neill's Physiology of 
Reproduction. 
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1.4 EXPERIMENTAL METHODS TO TRACK AND QUANTIFY HUMAN 
SPERMATOGONIAL STEM CELLS 
Studies on human cells and/or tissues are a valuable stepping stone toward clinical translation.  
However, these studies are challenged by the limited experimental tools for quantifying human 
spermatogonia and testing their function. Here I propose that reliable markers of human 
spermatogonia are those with expression limited to germ cells located on the basement 
membrane of human seminiferous tubules. Proteins that meet these criteria, based on personal 
experience and review of the literature include PLZF, GFRα1, GPR125, SALL4, LIN28, 
UCHL1, UTF1, FGFR3, EXOSC10, DSG2, CBL, SSEA4, CD9, OCT2 and SSX [103-113].   
In rodents, SSC transplantation is the gold standard that allows investigators to quantify 
spermatogonial stem cells by observing their biological potential to produce and maintain 
spermatogenesis in infertile recipient animals. Homologous species transplantation to test the 
function of human spermatogonial stem cells is not possible. Our laboratory previously 
established and validated a primate-to-nude mouse xenotransplantation assay for monkey SSCs 
[53, 114]. To enable this assay, we generated a rabbit anti-primate testis cell polyclonal antibody 
that specifically recognizes antigens in primate testis cells. This antibody did not exhibit 
immunoreactivity with untransplanted mouse seminiferous tubules (Figure 4A), but it does 
recognize colonies of human spermatogonia in mouse seminiferous tubules 2 months after 
transplantation (Figure 4C and D). Monkey and human SSCs do not produce complete 
spermatogenesis in mouse seminiferous tubules (probably due to evolutionary distance between 
primates and mice). However, the colonization foci are considered to be SSC derived, because 
(a) they exhibited typical spermatogonial appearance, including arrangement as singles, pairs, 
and chains on the basement membrane of seminiferous tubules, and expressed the germ cell 
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 Figure 4. Human-to-nude mouse xenotransplantation assay. 
 
 
 
 
 
 
 
 
 
 
 
marker, VASA (Figure 4E and F). (b) Clusters are not “just survivors of the transplant,” because 
the transplanted cells were a single cell suspension (confirmed visually on a hemocytometer) that 
was filtered through a 35-μm strainer. The presence of chains of human germ cells clearly 
A rabbit anti-primate testis cell polyclonal antibody was previously generated that specifically recognizes 
antigens on primate (human and nonhuman) testis cells. (A) The antibody does not exhibit immunoreactivity 
with untransplanted mouse seminiferous tubules. (B) An isotype control antibody (rabbit IgG) does not exhibit 
immunoreactivity with mouse seminiferous tubules transplanted with human testicular cells. (C and D) The 
primate testis cell antibody cross-reacts with human testis cells and can be used to identify colonies of human 
spermatogonia in mouse seminiferous tubules 2 months after transplantation. Cells in colonies have a typical 
spermatogonial appearance, with large nuclear-to-cytoplasmic ratios, and are arranged as singles, pairs, and 
chains located on the basement membrane of seminiferous tubules. (E and F) The colonizing cells recognized by 
the primate testis cell antibody also express the germ cell marker VASA. Mouse seminiferous tubules are 
demarcated by dashed white lines. Scale bar: 100 μm. Reprinted with permission from Dovey SL and Valli H et 
al., J Clin Invest. 2013 Apr 1;123(4):1833-43, Copyright (2014). 
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indicates proliferation after engraftment. (c) These colonies are unlikely to arise from 
differentiating B spermatogonia, because a colonizing human B spermatogonia would produce a 
spermatocyte at its next division and migrate off the basement membrane. Therefore, 
spermatogonial colonies with 4 or more cells located on the basement membrane of seminiferous 
tubules must originate from human Adark or Apale spermatogonia, which are considered reserve 
and active SSCs, respectively [114-117].  
Additionally, immunohistochemical assessment of human colonizing events in recipient 
mouse testes indicate that colonizing cells are located on the basement membrane of 
seminiferous tubules and contain enolase 2 (ENO2) positive undifferentiated human 
spermatogonia as well as ENO2 negative human cells that are presumably more differentiated 
germ cells (Figure 5).  
 
 Figure 5. Rabbit anti-primate antibody and ENO2 co-staining of recipient mouse testes 
xenotransplanted with human testis cells in cross-section. 
 
 
 
At present, human to nude mouse xenotransplantation is the best functional assay to test 
the spermatogonial stem cell-like potential of a test cell population [94, 95, 104, 106, 112, 118-
120]. This method does not recapitulate complete spermatogenesis from transplanted cells like 
Immunofluorescence co-staining for the primate antibody (A and C) and ENO2 (B and C) in human to nude mouse 
xenotransplants testis. DAPI staining (blue) identifies all the nuclei. Scale bars = 50 µm. Reprinted from Valli et al., 
Fertil Steril. 2014 Aug;102(2):566-580, with permission from Elsevier Ltd. 
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mouse to mouse SSC transplantation, probably due to evolutionary distance between humans and 
mice. However, human-to-nude mouse xenotransplantation does assay the ability of transplanted 
cells to migrate to the basement membrane of seminiferous tubules, proliferate to produce 
characteristic colonies of spermatogonia and persist long term [104, 106, 112, 118, 119].  
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2.0  CHARACTERIZATION OF HUMAN SPERMATOGONIAL STEM CELLS 
2.1 INTRODUCTION 
Spermatogenesis is a process that produces millions of sperm per day in postpubertal mammals 
[1-3]. At the foundation of spermatogenesis are spermatogonial stem cells (SSCs) that balance 
self- renewing divisions with differentiating divisions to maintain the stem cell pool and fuel 
spermatogenesis, respectively [4, 5, 44]. Despite their importance to male fertility, there is 
limited knowledge about the molecular characteristics of the human SSCs, which are typically 
described as Adark and Apale spermatogonia based on nuclear staining intensity with hematoxylin 
[44, 48, 121].  
The majority of information about the molecular phenotype of spermatogonia has been 
generated using rodent models and although no SSC specific marker has been identified several 
markers that are expressed by stem and/or progenitor cells have been described (e.g. GFRα1, 
POU3F1, POU5F1 (OCT4), ZBTB16 (PLZF), NGN3, NANOS2, NANOS3, SOHLH1, 
SOHLH2, FOXO1, ITGA6 (α6-integrin, CD49f), LIN28, ID4, PAX7, UTF1, CDH1, GPR125, 
ITGB1 (β1-integrin, CD29), EPCAM (CD326), CD9 and THY1 (CD90) [13-43]). Rodent SSCs 
are only definitively identified by their ability to produce spermatogenesis when transplanted 
into the testes of infertile recipient mice, an assay that was first described by Brinster and 
colleagues [122, 123]. In the transplant bioassay, each colony of spermatogenesis produced in 
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the recipient testis arises from a single SSC and therefore allows quantification of the starting 
population of stem cells [124-127]. The combination of the transplant technique with 
fluorescence activated cell sorting (FACS) has provided insights about additional phenotypic 
features that can be used to isolate and enrich mouse spermatogonia. Mouse spermatogonia have 
the phenotype: ITGA6+, ITGB1+, THY1+, CD9+, GFRα1+, mitochondrial membrane potentialhigh, 
Rhodamine 123 (Rho123)low,  ITGAV (αv-Integrin, CD51)-, KIT (cKIT, CD117)-, MHC-I-, 
ALDH (aldehyde dehydrogenase) activity- and CD45-  [20, 29, 31, 128-133]. There is a lack of 
consensus about whether SSC activity can also be recovered in the Hoechst side population 
fraction of mouse testes [19, 134-136]. 
In humans, undifferentiated stem and progenitor spermatogonia have been described by 
classical descriptions of nuclear morphology as Adark and Apale spermatogonia [48, 137]. 
Information about the molecular phenotype of human spermatogonia has begun to emerge in the 
last few years. Based on immunofluorescence and colorimetric staining of adult human testicular 
sections, human spermatogonia on the basement membrane of the seminiferous tubules express 
UTF1, SALL4, ZBTB16, GFRα1, UCHL1, GPR125, LIN28,  EXOSC10, FGFR3, DSG2, CBL, 
SSX2 and OCT2 [26, 108, 109, 138-146]. Less is known about cell surface markers that could be 
used to isolate and enrich human SSCs. A few studies have reported enrichment of putative 
human SSCs by sorting based on cell surface marker expression of GPR125, SSEA4, ITGA6 and 
CD9 [112, 143, 145, 147], but currently only two studies have confirmed their results by 
demonstrating SSC colonizing activity in the xenotransplant assay. Magnetic activated cell 
sorting (MACS) revealed enrichment of SSC colonizing activity in the SSEA4+ and CD9+  
fractions of human testis cells [112, 145]. 
 17 
THY1, a glycophosphatidylinositol anchored cell surface protein, that belongs to the 
immunoglobulin-like superfamily of genes [148], has been shown to be expressed by neuronal 
cells, CD34 positive hematopoietic stem cells, fibroblasts and endothelial cells [149-155].  
THY1 is involved in diverse processes, including cell migration, cell-cell/cell-matrix interactions 
[156] and T-cell activation [157]. In testis, THY1 has been shown through transplantation assay 
to be a conserved spermatogonial stem cell marker in mice [19], rats [29] and non-human 
primates [53]. However, the expression of THY1 in human spermatogonia has been 
contradictory. He et al. [143] showed that THY1 expression is limited to a few rare cells on the 
basement membrane of seminiferous tubules, whereas Izadyar et al. [112] showed staining in the 
germ cells located toward the lumen of  the tubule and also in peritubular and interstitial cells. 
Both of these reports are based on immunofluorescence staining and no transplants were 
performed. Human to human transplants are not possible as a routine bioassay, but 
xenotransplants into the testes of infertile nude mice has emerged as a quantitative assay for 
human and nonhuman primate spermatogonia [26, 53, 94, 95, 112, 114, 118, 119, 145, 158, 159]. 
To help clarify this issue of whether THY1 is expressed by human SSCs, I fractionated 
human testis cell suspensions based on THY1 expression using FACS and MACS. The presence 
of undifferentiated stem or progenitor spermatogonia in the sorted fractions was evaluated by 
immunocytochemistry for SALL4 and human to nude mouse xenotransplantation. Similar 
experiments were performed for the cell surface markers ITGA6 (CD49f) and EPCAM (CD326), 
which are established markers of rodent spermatogonia [20, 29, 160]. 
ITGA6 is the integrin alpha chain 6. Integrins are cell surface proteins that are made up 
of an alpha chain and a beta chain and they provide a link between extracellular matrix proteins 
and the cytoskeleton [161]. ITGA6 has been shown to regulate glioblastoma stem cells [162] and 
 18 
is expressed by mouse mammary stem cells [163] and is crucial for the survival of the MCF-7 
cell line stem cells [164]. EPCAM (epithelial cell adhesion molecule) is a transmembrane 
glycoprotein that mediates homophilic cell-cell adhesion [165]. Modulation of Epcam activity is 
thought to affect cell migration, proliferation and invasion [165, 166] and overexpression of 
Epcam plays a role in cancer development [166-168]. 
Currently, no human data are available regarding whether spermatogonial markers used 
in FACS are also appropriate for MACS and vice versa. The choice of whether to use FACS or 
MACS depends on the desired output. FACS has limited throughput (~30 x 106 cells per day); it 
is fairly time consuming and requires specialized equipment and a skilled operator, but it allows 
high resolution selection of sorting gates. MACS has a lower resolving power, but is generally a 
faster and is a higher throughput sorting strategy that can be performed on the laboratory bench 
and does not require specialized equipment. A single adult human testis that can be obtained for 
research through an organ donor program can contain over 1 billion cells, which is far beyond 
the typical sorting capacity of FACS. MACS can easily be scaled to accommodate this number 
of cells and maximize the use of this valuable human tissue resource for fundamental research. In 
addition, MACS is technically accessible and affordable, which will facilitate application for 
enriching SSCs in the clinical setting. 
FACS fractions were analyzed by immunocytochemistry for the human spermatogonial 
marker SALL4 [118, 139] and human-to-nude mouse xenotransplantation. SALL4 is a member 
of sal-gene family of transcription factors that is highly conserved between species [169-175]. 
SALL4 is expressed by the cells in an early embryo and is important for maintaining 
pluripotency of ES cells [176, 177].  In addition SALL4 is a conserved marker of spermatogonia 
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[139, 178, 179] and has been implicated in the regulation of spermatogonial differentiation in 
mice [178]. MACS fractions were analyzed by human-to-nude mouse xenotransplantation.  
Analyses of FACS fractions indicated that, all three cell-surface markers, EPCAMdim, 
ITGA6+ and THY1dim can be used to effectively isolate and enrich human SSCs from a 
heterogeneous testis cell suspension.  In contrast, only ITGA6 was suitable for sorting human 
SSCs by MACS, as THY1 and EPCAM provided no enrichment. 
2.2 MATERIALS AND METHODS 
Animals 
All experiments utilizing animals were approved by the Institutional Animal Care and 
Use Committees of the Magee-Womens Research Institute and the University of Pittsburgh and 
were performed in accordance with the National Institute of Health guidelines for the care and 
use of animals (assurance # A3654-01).  
 
Preparation of Human Testicular Tissue 
Deidentified, normal adult human testicular tissue was obtained through the University of 
Pittsburgh Health Sciences Tissue Bank and Center for Organ Recovery and Education (CORE) 
under University of Pittsburgh IRB #0506140. Following the removal of tissue, it was 
transported to the laboratory on ice in Lactated Ringer’s solution. Cells were recovered from 
human testicular tissue using a two-step enzymatic digestion described previously [53, 114, 118]. 
Briefly, testicular tissue was digested with collagenase type IV for 5 minutes at 37°C on the 
shaker (250 rpm), then shaken vigorously and incubated for another 3 minutes and if necessary 2 
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additional minutes at 37°C on the shaker. The tubules were then sedimented by centrifugation at 
200xg for 5 minutes and washed with Hank’s Balanced Salt Solution (HBSS, Gibco). The 
tubules were then digested with 0.25% trypsin/EDTA and DNase I. The suspension was 
triturated vigorously 3-5 times and incubated at 37°C for 5 minutes. The process was repeated in 
5 minute increments for up to 15 minutes total. The digestion was stopped by adding 10% fetal 
bovine serum (FBS) and the cells were strained through 70µm strainer (Becton Dickson). The 
cells were pelleted by centrifugation at 600xg for 15 minutes. Cells were then suspended in 
minimal essential medium α (MEM α) + 10% FBS at a concentration of 40 x 106 cells/mL and 
aliquoted in cryovials. An equal volume of cryopreservation medium consisting of MEMα + 
20% FBS + 20% dimethylsulphoxide (DMSO) was added drop-wise, making the final 
concentration 20 x 106/mL in MEMα/15% FBS/10% DMSO). The vials were frozen at a 
controlled rate using Nalgene freezing containers (Nalgene-Nunc International) or a CryoMed 
controlled-rate freezer (Thermo Scientific) and then stored in liquid nitrogen. For experiments, 
the cells were thawed rapidly at 37°C, washed and suspended in MEMα medium containing 10% 
FBS.   
 
Fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS) 
For FACS, the frozen and thawed human testis cell suspension was stained on ice in 
Dulbecco’s phosphate-buffered saline (D-PBS) containing 10% FBS for 20 min with 
fluorescent-conjugated antibodies (THY1-APC, clone 5E10, 0.5 µg/106 cells and ITGA6 -PE 
clone GoH3, 20 µl/106 cells; Becton Dickinson; EPCAM-PE, clone 9C4, 20 µl/106 cells; 
BioLegend). Cells were then washed twice with D-PBS to remove unbound primary antibody, 
and filtered through a 35µm strainer (Becton Dickinson). Propidium iodide (0.5µg/ml, BD 
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Bioscience) was added to distinguish between live and dead cells. FACS analysis was done using 
FACSvantage SE (Beckton, Dickinson) and the positive staining was identified by comparison to 
appropriate isotype control in order to correct for non-specific binding. Sorting gates were 
established based on level of marker expression as well as exclusion of dead cells stained with 
propidium iodide and exclusion of cells exhibiting non-specific binding or autofluorescence.  
The MACS protocol was similar to that of FACS, except after fluorescent-conjugated antibody 
staining (THY1-PE, ITGA6 –PE; Becton Dickson; and EPCAM-PE; BioLegend) and washes, 
anti-PE Microbeads (2 µl/106 cells; Miltenyi Biotec) were used to detect the fluorophore on the 
primary antibody. The cells were then sorted on a MACS column (Miltenyi Biotec) into positive 
(bound) and negative (flow through) fractions.  
 
Immunocytochemistry 
Cells from FACS and MACS were spotted on Superfrost slides and fixed with methanol. 
The cells were then rehydrated with D-PBS and blocked with a buffer containing 3% bovine 
serum albumin and 5% normal goat serum in order to eliminate nonspecific binding. Rabbit anti- 
SALL4 (1:500; ab29112, Abcam) antibody was added to the cells and incubated for 90 min at 
room temperature. Isotype matched normal IgG was used as negative control. Primary antibody 
was detected using goat anti-rabbit AlexaFluor-488 conjugated secondary antibody (1:200, 
Invitrogen). The slides were mounted with VectaShield (Vector Laboratories) mounting medium 
containing DAPI for detection of all nuclei and the staining was observed with a Nikon Eclipse 
E600 Fluorescence microscope and images captured with MetaView Digital Imaging software.  
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Immunofluorescence 
Human testicular tissue fragments were fixed with 4% paraformaldehyde (PFA) 
overnight, paraffin-embedded and sectioned (5 µm). The tissue slides were de-paraffinized, 
rehydrated, incubated for 30 minutes in sodium citrate buffer (10 mM sodium citrate, pH 6.0, 
0.05% Tween-20) for antigen retrieval. The tissue was then blocked with a buffer containing 3% 
bovine serum albumin and 5% normal serum from the host species of the secondary antibody. 
Subsequently, sections were stained for 90 minutes at room temperature with the following 
primary antibodies in antibody diluent: mouse anti-UTF1 (1:50, MAB4337, Millipore) goat anti-
ZBTB16 (1:50; AF2944, R&D Systems),  rabbit anti- KIT; goat anti-KIT (1:400; A4502, 
DakoCytomation; 1:50; AF332, R&D Systems), rabbit anti-SALL4 (1:500; ab29112, Abcam; 
1:40; ab181087, Abcam), mouse anti-ENO2 (1:500, LS-B2890, LSBio), rabbit anti-UCHL1 
(1:1000, 7863-0507, Biogenesis), rabbit anti-EPCAM (1:200; ab71919, Abcam), rabbit anti-
ITGA6 (1:100; ab75737, Abcam). Isotype matched normal IgG was used as negative control. 
Primary antibodies were detected using AlexaFluor-488 or AlexaFluor-568 conjugated 
secondary antibodies (1:200, Invitrogen). The slides were mounted with VectaShield mounting 
medium containing DAPI (Vector Laboratories) for detection of nuclei. Sections were observed 
with a Nikon Eclipse E600 fluorescence microscope and images captured with MetaView Digital 
Imaging software. For the quantification of marker overlap, single-positive cells for each marker 
and double-positive cells were counted in cross-sections of seminiferous tubules. Total stained 
cell numbers were divided by the number of tubular cross-sections (at least 100 per sample x 3 
replicate samples). 
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Colorimetric immunohistochemistry 
Human testicular tissue fragments were fixed with 4% PFA overnight, paraffin-
embedded and sectioned (5 µm). The tissue slides were de-paraffinized, rehydrated, incubated 
for 30 minutes in sodium citrate buffer (10 mM sodium citrate, pH 6.0, 0.05% Tween-20) for 
antigen retrieval. The tissue was then incubated in peroxidase block for 10 minutes and washed 
in PBS and blocked with a buffer containing 3% bovine serum albumin and 5% normal goat 
serum. Subsequently, sections were stained for 90 minutes at room temperature with rabbit anti-
UCHL1 (1:1000, 7863-0507, Biogenesis). Isotype matched normal IgG was used as negative 
control. Primary antibody was detected using goat anti-rabbit HRP conjugated secondary 
antibody (1:200, sc-2054, Santa Cruz Biotechnology) for 30 minutes. Metal enhanced DAB 
substrate kit was used to detect staining (Thermo Scientific). The tissue was then counterstained 
with Periodic acid-Schiff and hematoxylin (Sigma-Aldrich) to enable identification of Adark and 
Apale spermatogonia. 
 
Whole mount immunohistochemistry 
Human testicular tissue was teased apart using Collagenase type IV (1mg/mL) and 
DNase I (1mg/mL) in D-PBS. The tissue was then fixed overnight with 4% PFA. The tubules 
were permeabilized using PBS and 0.1% Triton-X and blocked with a blotto milk solution in D-
PBS (D-PBS +0.02 mg/mL blotto dry milk powder + 5%Triton-X) and stained with a rabbit anti-
UCHL1 (1:500, 7863-0507, Biogenesis) and goat anti-KIT (1:50; AF332, R&D Systems) 
primary antibodies overnight at 4°C. The primary antibodies were detected with donkey anti- 
rabbit IgG AlexaFluor568 and donkey anti-goat IgG AlexaFluor488 (1:200, Invitrogen). Finally, 
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the seminiferous tubules were mounted with VectaShield mounting media containing DAPI 
(Vector Laboratories) with raised cover slips and imaged with fluorescent microscopy.   
 
Xenotransplantation and whole mount immunofluorescent quantification of human SSC 
colonizing activity in mouse seminiferous tubules 
The human-to-nude mouse xenotransplantation was performed as a biological assay to 
investigate colonizing activity of putative human SSCs. Following FACS and MACS , unsorted 
and sorted testicular cell fractions were transplanted into the testes of busulfan-treated (40 
mg/kg; Sigma, at 5–6 weeks of age), immune-deficient nude mice (NCr nu/nu; Taconic, 
Germantown, NY), as previously described [53, 114, 118, 159].  Briefly, xenotransplantation 
was performed 5 weeks after busulfan treatment by injecting cell suspensions containing 10% 
trypan blue (Invitrogen) into the seminiferous tubules of recipient mouse testes via the efferent 
ducts.  Approximately 7 µl of cell suspension was injected per testis. For quantitative analysis of 
colonization by human donor spermatogonia, the testes were recovered 8 weeks following 
transplantation, the tunica was removed, and the intact seminiferous tubules were dispersed 
gently with Collagenase IV (1mg/mL) and DNase I (1mg/mL) in D-PBS. The tubules were fixed 
for 4 hours in 4% PFA and the whole mount immunofluorescence was carried out by 
dehydrating samples in a graded series of methanol dilutions before incubating in 
MeOH:DMSO:H2O2 (4:1:1) solution for three hours. The tubules were then rehydrated, blocked 
with a blotto milk solution in D-PBS (D-PBS + 0.02 mg/mL blotto dry milk powder + 5%Triton-
X) and stained with a rabbit anti-primate testis cell primary antibody [114] at a 1:800 dilution 
overnight at 4°C. The primary antibody was detected with goat anti-rabbit IgG AlexaFluor488 
(1:200, Invitrogen). Finally, the seminiferous tubules were mounted with VectaShield mounting 
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media containing DAPI (Vector Laboratories) with raised cover slips and imaged with 
fluorescent microscopy.  Spermatogonial colonies were counted based on the following criteria: 
at least 4 cells exhibiting spermatogonial morphology (ovoid shape with high nuclear to 
cytoplasmic ratio) and located on the basement membrane in a continuous area of recipient 
seminiferous tubule ( 100 µm between cells). 
Statistical Analysis 
I  analyzed the data using linear mixed effect models, and performed Tukey’s tests, as 
described in [180], to compare differences among the percent of SALL4+ cells in unsorted versus 
sorted cell fractions in the immunocytochemistry experiments and colonizing activity in the 
human-to-nude mouse xenotransplant bioassay.      
2.3 RESULTS 
2.3.1 Acquisition of human testicular tissue 
Testicular tissues used in this study were obtained from a total of 12 post-pubertal organ donors 
(Age 14-50). Testes weighed 11.3 to 26.0 grams and produced a theoretical yield (after 
correcting for tissue removed for pathology and immunofluorescence studies) of 1.4 x 109 ± 0.14 
x 109 cells per donor. All human testis cell suspensions used in this study were cryopreserved as 
described above and thawed at a later date for experimentation. Human testicular cells used in 
this study were frozen for periods of time ranging from 1 month to 15 months.   
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2.3.2 Immunohistochemical staining of human testicular sections 
Immunohistochemical co-staining analysis was done to investigate the co-expression of known 
mouse and/or non-human primate spermatogonia markers in adult human testis. ZBTB16 and 
SALL4, which mark most stem and progenitor spermatogonia in rodents [179], were expressed 
in cells located on the basement membrane, consistent with location of undifferentiated 
spermatogonia. Roughly 89% of ZBTB16 positive cells were also positive for SALL4 (Figure 6 
A-D), but also a small population of ZBTB16 positive cells (11%) did not express SALL4. 
Similarly, a sub-population of SALL4 positive cells also did not express ZBTB16 (11%) (Figure 
6 D). Co-staining with SALL4 and KIT, an established marker of differentiating spermatogonia, 
revealed almost no overlap between these two markers (Figure 6E-H). These results suggest that 
SALL4 is not expressed by differentiating spermatogonia in human testis. UTF1 expression was 
also restricted to cells on the seminiferous tubule basement membrane (Figure 6 I-L). Co-
staining with UTF1 and SALL4 indicated that 65% of the SALL4 positive cells express UTF1, 
whereas 35% of expressed SALL4 only. Seventeen percent of UTF1 positive cells express UTF1 
only (Figure 6L). To confirm that UTF1 is not expressed by differentiating spermatogonia, I co-
stained UTF1 with a differentiation marker KIT (Figure 6M-P) and found that there is no overlap 
between these two markers. Based on these results, I believe that UTF1 is a more restricted 
marker of stem and progenitor spermatogonia than SALL4. This interpretation is consistent with 
results of van Bragt and colleagues [28] who concluded that UTF1 is restricted to Asingle, Apaired 
and Aaligned4 spermatogonia in rats. Similar to SALL4, UCHL1 expression is less restricted than 
UTF1 (Figure 6Q-T) with 75% of UCHL1 positive cells co-expressing UTF1 and 25% 
expressing UCHL1 only. UTF1 positive cells were UCHL1 positive 87% of the time and UTF1 
only positive13% (Figure 6T). Co-staining with KIT, confirms that UCHL1 is not expressed 
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Figure 6. Expression of ZBTB16, UTF1, SALL4, UCHL1, ENO2 and KIT in human seminiferous 
epithelium. 
  
 
 
 
 
 
 
 
by differentiating cells, demonstrated by limited overlap with KIT (Figure 6U-X). I also 
analyzed the expression pattern of a novel marker, ENO2, which exhibited nearly complete 
overlap of expression with UCHL1 (Figure 6Y-BB). By transitive logic, ENO2 is a marker of 
undifferentiated spermatogonia in humans because it exhibits nearly complete overlap with 
UCHL1, which has very little overlap with KIT.  The overlap between ENO2 and SALL4 is less 
complete, with 78% of the ENO2 positive cells expressing SALL4 and 12% expressing ENO2 
only (Figure 6CC-FF). These results indicate that ENO2 expression is slightly broader than 
SALL4 expression in human undifferentiated spermatogonia. Figure 7 summarizes our 
interpretation of these results in terms of the order and breadth of marker expression by human 
spermatogonia.   
Immunofluorescence co-staining for SALL4 and ZBTB16 (A-D), SALL4 and KIT (E-H), UTF1 and SALL4 (I-
L), UTF1 and KIT (M-P), UTF1 and UCHL1 (Q-T), UCHL1 and KIT (U-X), UCHL1 and ENO2 (Y-BB) and 
SALL4 and ENO2 (CC-FF) in adult human testis. DAPI staining (blue) identifies all the nuclei. The bar graphs 
show quantification and relative proportion of each co-staining. The quantification is shown as the mean number 
of positive cells per cross-section of a seminiferous tubule. At least 100 seminiferous tubules were counted from 3 
different organ donors. Bar graphs in D, H, L, P, T, X and BB indicate the mean number of marker positive cells 
per cross-section. Error bars represent SEM. Scale bars = 100 µm. Reprinted from Valli et al., Fertil Steril. 2014 
Aug;102(2):566-580, with permission from Elsevier Ltd. 
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Figure 7. Summary of marker expression in adult human testis. 
 
 
 
 
 
2.3.3 Correlation of spermatogonial markers with dark and pale descriptions of nuclear 
morphology and clone size 
To correlate molecular markers of human spermatogonia described in this study with classical 
descriptions of nuclear staining intensity (Adark and Apale), I performed colorimetric 
immunohistochemistry for UCHL1 followed by Periodic Acid-Schiff and hematoxylin 
Colored bars indicate the overlap of markers based on data from Figure 6. Shaded area indicates range in data. 
UTF1 seems to be the most restricted marker of human spermatogonia, followed by ZBTB16 and SALL4. 
There is also almost no overlap between these markers and differentiation marker KIT. UCHL1 and ENO2 are 
more widely expressed in cells on the basement membrane of the seminiferous tubule and have slightly more 
overlap with KIT. Reprinted from Valli et al., Fertil Steril. 2014 Aug;102(2):566-580, with permission from 
Elsevier Ltd. 
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counterstaining. The results in Figure 8A confirm that UCHL1 is expressed by human Adark and 
Apale  spermatogonia.  
 
 
Figure 8. UCHL1 expression in adult human testis.  
 
 
 
.  
 
 To correlate UCHL1 expression with clone size, I performed immunofluorescent 
spermatogonia, which are considered the reserve and active stem cells of the human testis, 
respectively [51, 181]. To correlate UCHL1 expression with clone size, I performed 
immunofluorescent analysis of UCHL1 expression in whole mount preparations of human 
seminiferous tubules. UCHL1 was expressed by cells located on the basement membrane of the 
 (A) UCHL1 staining in Periodic Acid-Schiff & Hematoxylin stained adult human testis section. UCHL1 is 
expressed by Adark and Apale spermatogonia. (B and D) UCHL1 and (C and E) KIT staining in whole mount 
staining of adult human testis. (F) UCHL1 clones are smaller (mostly 1-4 cells), whereas KIT clones tend to be 
bigger (more than 8). Scale bar = 50 µm. Reprinted from Valli et al., Fertil Steril. 2014 Aug;102(2):566-580, 
with permission from Elsevier Ltd. 
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seminiferous tubules and arranged as single cells and clones of 2, 4 and sometimes 8 
interconnected cells.  In contrast, KIT expressing cells were typically arranged in clones of 4, 8 
and sometimes 16 interconnected cells (Figure 8B-F). The density of undifferentiated 
spermatogonia on the basement membrane of human seminiferous tubules appears greater than 
in rodents (Figure 9A and D), whereas KIT+ differentiating spermatogonia are considerably less 
dense in human tubules than in mouse (Figure 9B and E). 
  
Figure 9. Whole-mount immunohistochemistry of seminiferous tubules from mouse and human 
testes. 
 
 
 
2.3.4 Immunohistochemical evaluation of cell surface markers in adult human testes 
THY1, ITGA6 and EPCAM are cell surface markers that have each been used to isolate and 
enrich spermatogonial stem cells in other species [19, 20, 29, 53].  Previous studies indicated that 
Whole-mount immunofluorescence analysis of the undifferentiated spermatogonia marker, SALL4 (A), 
differentiating spermatogonia marker, KIT (B) and co-staining of SALL4 and KIT (C) in mouse. Whole-mount 
immunofluorescence analysis of undifferentiated spermatogonia marker UCHL1 (D), differentiating spermatogonia 
marker KIT (E) and co-staining of UCHL1 and KIT (F) human. Scale bar = 100µm.  
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these cell surface markers are conserved in human testes [112, 118, 143, 147] and I hypothesized 
that each could be used to isolate and enrich human SSCs by FACS and/or MACS.  I was not 
able to confirm the expression of THY1 in adult human testes by immunohistochemistry in this 
study. However, others have reported that this marker is expressed in human testes [112, 143, 
147].  
Immunohistochemical analysis of ITGA6 expression in normal adult human testis 
sections indicated that this antigen is expressed by many germ cells, including cells located on 
the basement membrane of seminiferous tubules (Figure 10A-C) and that EPCAM is expressed 
primarily by cells on the basement membrane of the seminiferous tubules, as well as a few cells 
located more towards the lumen (Figure 10D-F). 
 
Figure 10. ITGA6 and EPCAM expression in adult human testis sections.  
 
 
 
 
Immunofluorescence staining for ITGA6 (A and C) and EPCAM (D and F) in adult human testis. DAPI staining 
(blue) (B and E) identifies all the nuclei. Scale bars = 50 µm. Reprinted from Valli et al., Fertil Steril. 2014 
Aug;102(2):566-580, with permission from Elsevier Ltd. 
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2.3.5 Expression of THY1 in adult human testicular cell suspensions 
THY1 is a marker of mouse, rat and non-human primate SSCs [19, 29, 53] as well as a marker 
for mouse and human hematopoietic stem cells [182-184]. Therefore, I hypothesized that THY1 
is a marker for human SSCs and analyzed the expression on adult human testicular cells using 
FACS and MACS. Staining of adult human testis cell suspensions with THY1 identified three 
populations of cells, designated THY1 bright, THY1 dim and THY1 negative, based on their 
level of fluorescence, plotted against a negative PE axis, which helps to identify and eliminate 
autofluorescence (Figure 11A). The THY1 bright, dim and negative fractions represented 12.2 ± 
4.2%, 19.0 ± 4.0% and 46.5 ± 7.0% of the live cells, respectively. Immunofluorescence staining 
revealed that 6.8 ± 0.1% of unsorted human testicular cells express human spermatogonia marker 
SALL4, compared to 7.2 ± 0.3% in the THY1 negative fraction (p<0.01), 15.5 ± 0.9% in the 
THY1 dim fraction (p<0.01) and only 0.4 ± 0% in the THY1 bright  fraction (p<0.01) (Figure 
11B). To confirm the immunocytochemistry results and to functionally correlate THY1 
expression in adult human testis to SSC colonizing activity, the human-to-nude mouse 
xenotransplantation assay was performed. The transplant results confirm that SSC colonizing 
activity was depleted from THY1 bright fraction (0.57 ± 0.6 colonies/105 cells; p<0.01 compared 
to the unsorted controls). The majority of SSC colonizing activity was recovered in the THY1 
dim fraction (48.2 ± 36.3 colonies/105 cells; p<0.01 compared to the unsorted controls), 
compared to 9.03 ± 3.8 and 9.67 ± 8.1 colonies/105 cells in unsorted and THY1 negative 
fractions, respectively (Figure 11C). Based on these results, there is roughly a 5-fold enrichment 
of SSC colonizing activity in the THY1 dim fraction of human testis cells.  
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 Figure 11. FACS sorting and characterization of THY1 expression in adult human testes. 
 
 
 
 
 
 
 
 
 
 
 
 
(A) FACS was used to characterize and sort human testicular cells based on the level of THY1 expression. Based 
upon THY1-APC staining intensity and negative PE autofluorescence, three populations were identified – 
THY1bright, THY1dim and THY1neg. Negative gates were defined by analysis of human testis cells stained using 
APC-conjugated isotype control antibodies. (B) After the sort, all sorted fractions, as well as the unsorted cells, 
were fixed and immunocytochemistry for SALL4 was performed. SALL4 positive cells were enriched in the THY1 
dim fraction compared to the unsorted cells. (C) To confirm the ICC results, human-to-nude mouse xenotransplants 
were also performed. Two months after transplant, colonies of human spermatogonia were identified in mouse 
recipient testes. (C inset) Examples of colonies of human spermatogonia in whole mount preparations of recipient 
mouse seminiferous tubules stained with the rabbit anti-primate antibody.  Colonies in each recipient testis were 
counted and normalized to 105 viable cells transplanted per testis. (D-G) Representative images of SALL4 staining 
from each sorted fraction and unsorted cells. At least 10 views were counted from each fraction based on DAPI 
staining and SALL4 staining. Different letter indicate P < 0.01, same letters indicate P > 0.05. Bar graphs in B and 
C are presented as mean ± SEM. Scale bar = 100 µm. Reprinted from Valli et al., Fertil Steril. 2014 
Aug;102(2):566-580, with permission from Elsevier Ltd. 
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2.3.6 Expression of ITGA6 in adult human testicular cell suspension 
To determine whether ITGA6 is expressed on human spermatogonia and could be used as a 
positive selection marker to enrich human SSCs, adult human testicular cell suspensions were 
stained with a PE-conjugated antibody against ITGA6 and sorted by FACS. Two distinct 
populations of cells were gated; ITGA6 negative and ITGA6 positive (Figure 12A), which 
represented 27.6 ± 7.6% and 11.6 ± 3.0% of the live cells, respectively. Immunocytochemistry of 
the ITGA6 sorted fractions and unsorted cells revealed that 13.8 ± 6.2% of cells in the ITGA6 
positive fraction were SALL4 positive (Figure 12B and F), compared to 2.6 ± 0.2% in the 
unsorted cell population (p<0.01) (Figure 12B and D). SALL4 positive cells were depleted from 
the ITGA6 negative fraction (0.38 ± 0.1%; p<0.01 compared to the unsorted controls; Figure 12B 
and E). To confirm the immunocytochemistry results, colonizing activity in ITGA6 sorted and 
unsorted cells was assessed by xenotransplantation into nude mouse testes.  
 
 36 
 Figure 12. FACS sorting and characterization of ITGA6 expression in adult human testes. 
 
 
 
 
 
 
 
 
 
 
 
 
On average, cells in the ITGA6 positive fraction produced significantly more colonies in 
recipient mouse testis (49.3 ± 14.0 colonies/105 cells transplanted) than the unsorted controls (4.1 
± 1.5 colonies/105 cells, p<0.01) or ITGA6 negative cells  (3.7 ± 3.5 colonies/105 cells) (Figure 
12C). Thus, SSC colonizing activity resides predominantly in the ITGA6 positive fraction of 
human testis cells and is enriched approximately 12-fold compared to the unsorted population. 
2.3.7 Expression of EPCAM in adult human testicular cell suspension 
To determine whether EPCAM is expressed on human spermatogonia and could be used as a 
positive spermatogonial selection marker, human testicular cell suspensions were stained with a 
PE-conjugated antibody against EPCAM and sorted using FACS. As demonstrated in Figure 13 
(A) FACS sorting for ITGA6 in human testis resulted in 2 different populations based upon ITGA6 -PE staining 
intensity and negative FITC autofluorescence – ITGA6 positive and ITGA6 negative. Negative gates were defined 
by analysis of human testis cells stained using PE-conjugated isotype control antibodies. (B) After the sort, all 
sorted fractions, as well as the unsorted cells, were fixed and immunocytochemistry for SALL4 was performed. 
SALL4 positive cells were enriched in the ITGA6 positive fraction compared to the unsorted cells. (C) To confirm 
the ICC results, human to nude mouse xenotransplants were also performed. Two months after transplant, colonies 
of human spermatogonia were identified in mouse recipient testes. (C inset) Example of a colony of human 
spermatogonia in whole mount preparations of recipient mouse seminiferous tubules stained with the rabbit anti-
primate antibody. Colonies in each recipient testis were counted and normalized to 105 viable cells transplanted per 
testis. (D-F) Representative images of SALL4 staining from each sorted fraction and unsorted cells. At least 10 
views were counted from each fraction based on DAPI staining and SALL4 staining. Different letters indicate P < 
0.01, same letters indicate P > 0.05. Bar graphs in B and C are presented as mean ± SEM. Scale bar = 100 µm. 
Reprinted from Valli et al., Fertil Steril. 2014 Aug;102(2):566-580, with permission from Elsevier Ltd. 
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populations of cells were identified following staining with EPCAM, based on their level of 
fluorescence and on side scatter of incident light, which provides a measure of intracellular 
complexity: EPCAM negative, EPCAM dim, and EPCAM bright. EPCAM is known to be 
expressed on SSCs in rats [29, 185]. Following sorting, each fraction of cells was fixed and 
stained with an antibody directed against SALL4 to quantify undifferentiated human 
spermatogonia. The majority of SALL4 positive spermatogonia were recovered in the EPCAM 
dim fraction (Figure 13B and F). Compared with 7.4 ± 1.8% of cells expressing SALL4 in the 
unsorted testicular cell population, 22.5 ± 3.3 % of cells in the EPCAM dim fraction expressed 
SALL4 (P < 0.0001). The EPCAM negative and EPCAM bright fractions were virtually depleted 
of SALL4–expressing cells (P < 0.0001 compared with unsorted). The human-to-nude mouse 
xenotransplantation assay was used to quantify SSC activity in unsorted, EPCAM negative, 
EPCAM dim, and EPCAM bright fractions. Unsorted human testicular cells produced 8.5 ± 1.5 
colonies of spermatogonia per 105 viable transplanted cells (Figure 13C). The EPCAM dim 
fraction produced 49 ± 9.2 colonies of spermatogonia per 105 viable transplanted cells, 
representing an approximate 6-fold enrichment compared with the unsorted population (P < 
0.0001). Mirroring the SALL4 data, colony numbers were significantly reduced in the EPCAM 
negative and EPCAM bright fractions (P < 0.01 compared with unsorted controls). Thus, I 
conclude, based on SALL4 immunocytochemistry (Figure 13B and D-G) and the 
xenotransplantation results (Figure 13C), that SSC activity resides in the EPCAM dim fraction of 
human testis cells. 
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Figure 13. FACS sorting and characterization of EPCAM expression in adult human testes.  
 
 
 
 
 
 
 
  
 
 
 
 (A) FACS was used to characterize and sort human testicular cells based on the level of EPCAM expression. 
Based upon EPCAM-PE staining intensity and negative PE autofluorescence, three populations were identified – 
THY1bright, THY1dim and THY1neg. Negative gates were defined by analysis of human testis cells stained using 
APC-conjugated isotype control antibodies. (B) After the sort, all sorted fractions, as well as the unsorted cells, 
were fixed and immunocytochemistry for SALL4 was performed. SALL4 positive cells were enriched in the 
THY1dim fraction compared to the unsorted cells. (C) To confirm the ICC results, human-to-nude mouse 
xenotransplants were also performed. Two months after transplant, colonies of human spermatogonia were 
identified in mouse recipient testes. (C inset) Examples of colonies of human spermatogonia in whole mount 
preparations of recipient mouse seminiferous tubules stained with the rabbit anti-primate antibody. Colonies in 
each recipient testis were counted and normalized to 105 viable cells transplanted per testis. (D-G) Representative 
images of SALL4 staining from each sorted fraction and unsorted cells. At least 10 views were counted from each 
fraction based on DAPI staining and SALL4 staining. Different letters indicate P < 0.01, same letters indicate P > 
0.05. Bar graphs in B and C are presented as mean ± SEM. Scale bar = 100 µm. Reprinted with permission from 
Dovey SL and Valli H et al., J Clin Invest. 2013 Apr 1;123(4):1833-43, Copyright (2014). 
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2.3.8 Enrichment of human spermatogonia using MACS  
Analysis of FACS indicated that ITGA6, THY1 and EPCAM can be used to effectively isolate 
and enrich human SSCs from a heterogeneous testis cell suspension. However, the FACS sorting 
approach has limited throughput (~30 x 106 cells per day). Therefore, I evaluated a higher 
throughput sorting approach (MACS) to maximize the use of human testicular cells and compare 
the results to FACS. I evaluated the fractionation of human testis cells by THY1 MACS where 
there is no option to distinguish between bright and dim expression of THY1. The cells were 
sorted into THY1 positive (bound) and negative (flow through) fractions using MACS and then 
transplanted into nude mouse testes to analyze SSC colonizing activity relative to unsorted 
human testis cells. Unsorted cells produced 4.8 ± 2.5 colonies/105 cells, compared to 6.1 ± 2.0 
and 7.3 ± 3.7 colonies/105 cells in THY1 negative and THY1 positive fractions, respectively (P 
>0.05, compared to unsorted and each other), indicating that MACS did not effectively 
fractionate SSC colonizing activity based on THY1 expression (Figure 14A). Similar to the 
THY1 FACS results in this study, the SSC colonizing activity is enriched in the EPCAM dim 
fraction of human testis cells. Therefore, it is not surprising that MACS did not effectively 
fractionate SSC colonizing activity from human testis cells based on EPCAM expression (Figure 
14B). 
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Figure 14. MACS sorting of human testicular cells for THY1, EPCAM and ITGA6. 
 
 
 
 
 
 
 
 
In contrast, MACS was effective for isolation and enrichment of human SSC colonizing 
activity based on ITGA6 expression (Figure 14C). SSC colonizing activity in the ITGA6 positive 
MACS fraction was enriched over 3-fold  (9.6 ± 0.9 colonies/105 cells) compared to the unsorted 
fraction (2.9 ± 0.8 colonies/105 cells ; P < 0.05; Figure 14C). SSC colonizing activity was nearly 
depleted in the ITGA6 negative fraction, which produced only 0.3 ± 0.2 colonies/105 cells, 
indicating that almost all SSCs were recovered in the ITGA6 positive fraction.  
2.4 DISCUSSION 
In rodents, SSCs are defined by their ability to establish and maintain spermatogenesis when 
transplanted into infertile mouse testis [101, 122, 123, 186]. Although there is no specific 
molecular marker of rodent SSCs (except possibly ID4 and PAX7 [22, 43]), stem and progenitor 
spermatogonia can be described collectively by expression of some or all of the following 
markers GFRα1, POU3F1, POU5F1, ZBTB16, NGN3, NANOS2, NANOS3, SOHLH1, 
Human testicular cells were MACS sorted into 2 fractions – negative (flow through) and positive (bound). Both 
positive and negative fractions from MACS, as well as unsorted cells, were transplanted into nude mouse testis. 
(Inset A, B and C) Two months after transplant, colonies of human spermatogonia were identified in whole 
mount preparations of recipient mouse seminiferous tubules using the rabbit anti-primate antibody. Colonies in 
each recipient testis were counted and normalized to 105 viable cells transplanted per testis. (A and B) For THY1 
and EPCAM, no significant difference was found between the unsorted cells and the sorted fractions (P > 0.05). 
(C) ITGA6 positive fraction was enriched roughly 3 fold compared to unsorted cells (P < 0.05). Bar graphs are 
presented as mean ± SEM. Scale bar = 100 µm. Reprinted from Valli et al., Fertil Steril. 2014 Aug;102(2):566-
580, with permission from Elsevier Ltd. 
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SOHLH2, FOXO1, ITGA6, LIN28, ID4, PAX7, UTF1, CDH1, GPR125, ITGB1, EPCAM, CD9 
and THY1 [13-43, 160, 187], and by their clonal arrangement on the basement membrane of 
seminiferous tubules (Asingle, Apaired, Aaligned; [188]). In humans, stem spermatogonia are 
described primarily as Adark and Apale based on the intensity of nuclear staining with hematoxylin 
[44, 48, 121]. There is limited information about how dark and pale descriptions of nuclear 
morphology correlate with transplantation potential, molecular markers or clone size. 
Here I show that spermatogonia on the basement membrane of human seminiferous 
tubules have the phenotype of SALL4+, ZBTB16+, UTF+, UCHL1+ and ENO2+ (Figure 6). The 
expression of SALL4, ZBTB16, UTF1 and UCHL1 in human testes has been reported previously 
[26, 109, 138, 139, 143, 146]. ENO2 is a gene that was identified by Oatley and co-workers 
because it is upregulated in ID4-GFP positive spermatogonia [189]. This is the first study to 
demonstrate that ENO2 is expressed by human spermatogonia and co-expressed with established 
markers of human stem and progenitor spermatogonia (i.e., UCHL1 and SALL4) [139, 143].   
This is also the first study to quantify the expression of these markers at the cellular level and 
describe their expression relative to other stem and progenitor markers by co-staining. I believe 
this systematic molecular profiling will identify subpopulations of cells (e.g., putative stem, 
progenitor and differentiating cells) that will become the subject of future investigations.   
The majority of cells that express SALL4, ZBTB16, UTF1, UCHL1 and ENO2, do not 
express the differentiation marker KIT, as demonstrated by direct co-staining (i.e., UCHL1/KIT, 
SALL4/KIT and UTF1/KIT) or transitive logic (UCHL1/ENO2; Figure 6).  These results suggest 
that SALL4, ZBTB16, UTF1, UCHL1 and ENO2 mark human undifferentiated spermatogonia 
and immunohistochemical analysis confirms that UCHL1 is expressed by Adark and Apale 
spermatogonia, the putative SSCs in human testes (Figure 8). Examination of these markers in 
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whole mount preparations of seminiferous tubules provides novel insights about human 
spermatogenic lineage development. Our results indicate that UCHL1 tended to be expressed by 
smaller clones (1-4 cells) while KIT is expressed in larger clones (usually 8 or more cells). 
Collectively, these results indicate that several markers of rodent stem and progenitor 
spermatogonia are conserved in humans and that spermatogonial differentiation in humans is 
correlated with increased clone size and initiation of KIT expression, similar to rodents [21, 
179].   
Spermatogenesis is an extremely productive system that produces millions of sperm per 
gram of testicular tissue each day in rodents and humans [1-3].  However, our results suggest that 
the dynamics of spermatogenic lineage development in humans may be different than rodents.  
In rodents, rare undifferentiated spermatogonia are heavily outnumbered by transit-amplifying 
differentiated spermatogonia [9]. In contrast, I found that number of undifferentiated 
spermatogonia in human testes was greater than the number of KIT+ differentiated 
spermatogonia (Figure 6, 8 and 9). Thus, it appears that the highly productive spermatogenic 
system in rodents depends on a small pool of stem and progenitor spermatogonia and a large 
pool of transit-amplifying cells while the human spermatogenic lineage is characterized by a 
relatively larger pool of undifferentiated stem and progenitor cells and a smaller pool of transit 
amplifying cells. 
FACS is suitable for characterizing relatively small cell populations (≤30 x 106) and can 
be used to achieve significant enrichment of spermatogonial stem cells [19, 29, 53, 118, 133, 
160, 190-193]. When coupled with molecular marker screening (using markers that are restricted 
to stem and progenitor spermatogonia) and the stem cell transplant assay to validate sorted 
fractions, FACS can be a powerful tool for dissecting the molecular phenotype of SSCs.  In the 
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current study, I used SALL4 immunocytochemistry (ICC) to screen sorted cell populations.  I 
considered SALL4 an excellent marker for screening human stem and progenitor spermatogonia 
because it is conserved in mice [139, 178, 179], rats (Gassei and Orwig, unpublished), monkeys 
[139] and humans [139], including expression by human Adark and Apale spermatogonia [139]. 
SALL4 ICC provided a rapid assessment of sorted fractions and was an excellent predictor of the 
results from human-to-nude mouse SSC xenotransplantation, which has an inherent two month 
delay to analysis. Based on the data presented here, I believe that UTF1, ZBTB16, UCHL1 and 
ENO2 would also be good markers to rapidly screen for human stem and progenitor 
spermatogonia. 
SSC transplantation is the experimental “gold standard” for assaying spermatogonial 
stem cells [194, 195]. SSC transplantation in humans may someday be feasible in the clinical 
setting [196], but cannot be used as a routine bioassay. However, Nagano and coworkers 
demonstrated that human SSCs can engraft the testes of infertile, immune compromised mice 
[197]. Human SSCs do not produce complete spermatogenesis in mouse seminiferous tubules, 
but they do execute several functions that are consistent with the activity of SSCs: 1) they 
migrate to the basement membrane of seminiferous tubules without being phagocytosed by 
mouse Sertoli cells; 2) they proliferate to produce characteristic chains and networks of 
spermatogonia and 3) they persist for several months. Human-to-nude mouse 
xenotransplantation is becoming a routine bioassay for human SSCs [26, 94, 95, 112, 118, 145, 
197].    
Studies employing FACS followed by transplantation of sorted fractions have established 
that ITGA6, THY1 and EPCAM are markers of SSCs in rodents [19, 20, 29]. Similar 
methodology with FACS or MACS sorting followed by human-to-mouse xenotransplantation 
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has been used to demonstrate that CD9 and SSEA4 are markers of human SSCs [112, 145]. 
Human testis cells have also been fractionated by MACS based on expression of GPR125, THY1 
and ITGA6 [143, 147, 198], but stem cell activity in sorted fractions was not tested by 
transplantation.    
Flow cytometry analyses in the current study identified two distinct THY1 positive 
populations in the human testis that I designated dim and bright. SALL4 staining as well as 
xenotransplant results suggested that the majority of the SSCs were in the THY1 dim fraction 
and SSC colonizing activity in that fraction was enriched approximately 5-fold compared to 
unsorted human testis cells (Fig. 11C). Almost no SSCs are found in the THY1 bright fraction.  I 
obtained similar results for EPCAM, where the SSC colonizing activity was recovered in the 
EPCAM dim fraction of human testis cells and depleted in the EPCAM bright and EPCAM 
negative fractions (Figure 13). Interestingly, neither of these markers could be used to effectively 
fractionate and enrich SSC colonizing activity from the human testis using MACS. SSC 
colonizing activity was recovered in both the bound and flow through fractions and colonizing 
activity in each fraction was similar to unsorted controls (Figure 14A and B). Perhaps this result 
can be attributed to the low expression level of these two antigens in human SSCs. Considering 
our MACS results, it is noteworthy that THY1 MACS is routinely used to sort SSCs from mouse 
testes [192, 199-203]. These results may indicate that there are species-specific differences in the 
level of THY1 expression. Alternatively, these results may indicate technical differences 
between direct labeling with bead-conjugated THY1 primary antibodies (mouse) and indirect 
labeling using bead conjugated secondary antibodies (current study). The bead conjugated anti-
mouse THY1 antibodies did not cross-react with the human THY1 antigen (data not shown). 
Flow cytometric analysis of ITGA6 in human testis cells revealed only two distinct populations, 
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positive and negative, and the majority of SSC colonizing activity was recovered in the 
ITGA6positive fraction, which was enriched 12-fold compared to unsorted controls (Figure 
12C). In contrast to THY1 and EPCAM, cells with SSC colonizing activity could be effectively 
isolated and enriched from heterogeneous human testis cell suspensions using ITGA6 MACS. 
However, the level of enrichment achieved by ITGA6 MACS (3.3-fold) was less than ITGA6 
FACS (12-fold). Sorting resolution by FACS is typically greater than MACS because FACS 
allows for gating of cell populations based on simultaneous evaluation of several parameters, 
including viability (PI-), cell size (forward scatter of incident light), cell complexity (side scatter 
of incident light) and specific immunoreactivity (autofluorescent-, nonspecific binding-).   
I identified several proteins with expression limited primarily to undifferentiated 
spermatogonia (KIT- cells) located on the basement membrane of seminiferous tubules in human 
testes. These markers may provide insights into the molecular mechanisms that regulate the 
function of human SSCs and can be used to screen human cell populations or tissues for putative 
SSCs. In addition they can be used to validate newly discovered markers of human stem and 
progenitor spermatogonia using co-staining approaches similar to those employed in the current 
study to validate the expression of ENO2 in human undifferentiated spermatogonia. In this study 
I demonstrated that human SSCs have the cell surface phenotype THY1 dim, EPCAM dim, 
ITGA6 positive. SSEA4 and CD9 are also cell surface markers of human SSCs that have been 
validated by human-to-mouse xenotransplantation [112, 145]. These markers can now be used 
alone or in combination to achieve significant enrichment of human SSCs for downstream 
studies. MACS can also be used for isolation and enrichment of SSCs prior to initiation of SSC 
cultures, as previously described for mice [192, 204]. ITGA6 (current study), CD9 [145] and 
SSEA4 [112] are also amenable to immunomagnetic sorting, which has virtually unlimited cell 
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sorting capacity and will facilitate isolation of SSCs from human testes that can contain over one 
billion cells.   
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3.0  CRYOPRESERVATION OF HUMAN SPERMATOGONIAL STEM CELLS 
3.1 INTRODUCTION 
Improved therapies for cancer and other conditions have resulted in growing population of long-
term survivors. Unfortunately, some cancer treatments, like whole body radiation or alkylating 
chemotherapy, can render the patient infertile [205]. For grown men and pubertal boys, the 
established fertility preservation protocol involves cryopreserving a semen sample (Figure 15, 
top). However, that is not an option for prepubertal boys who do not make sperm yet. For these 
patients, there are several stem cell based technologies in the research pipeline that in the future 
may offer novel techniques to preserve and restore their fertility. Even though these techniques 
are not yet available, prepubertal patients could in the future benefit from testicular tissue 
cryopreservation now. The technique(s) might be available by the time the patients are ready to 
have a family. In that case, the prepubertal patient and his parents are counseled on the 
reproductive risks of the cancer therapy and if the parents decide to cryopreserve testicular 
tissue, a testicular biopsy is taken from the patient prior to the initiation of cancer treatment. The 
testicular biopsy is then cryopreserved in liquid nitrogen for possible future use [196, 206].  
The techniques in the research pipeline that may be available for these patients in the 
future include testicular tissue grafting (Figure 15, bottom, yellow boxes), organ culture (Figure 
15, bottom, yellow boxes), induced pluripotent stem cell (iPSC) derived germ cells (Figure 15, 
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bottom, red boxes) and SSC transplantation (Figure 15, bottom, blue boxes). Testicular tissue 
grafts from newborn mice, pigs and goats produced complete spermatogenesis when grafted 
under the skin of nude mice [207] and sperm obtained from the grafts were used to produce 
offspring in mice [208]. Prepubertal monkey testis tissue also produced complete 
spermatogenesis with fertilization-competent sperm after xenografting into nude mice [209]. 
Xenografting human testicular tissue has been less successful. No studies report production of 
full spermatogenesis; the most advanced stage of germ cell development reported is a 
spermatocyte [210-212]. Sato and colleagues demonstrated that organ culture of mouse testicular 
tissue pieces produces sperm that can be used to fertilize an oocyte and generate live offspring 
[213, 214]. Spermatogonial stem cell transplantation technique has been reported to regenerate 
spermatogenesis in mice, rats, goats, pigs, bulls, dogs and monkeys; donor derived progeny were 
produced in mice, rats, goats and sheep [70, 73-85, 90].  
For patients who did not cryopreserve sperm or spermatogonial stem cells or testicular 
tissue before cancer treatment, generation of transplantable germ cells or haploid gametes from 
patient-derived induced pluripotent stem cells (iPSCs) has been investigated (Figure 15, red 
boxes). Mouse ESCs and iPSCs can give rise to primordial germ cells, that when transplanted 
into an infertile mouse testes, restored spermatogenesis [215]. The sperm from the recipient mice 
were capable of fertilizing oocytes and produced live offspring. Generation of germ cells from 
nonhuman primate ESCs [216, 217] and human ESCs and/or iPSCs [218-221] has been reported, 
including evidence of haploid cells in some cases. 
To date, published reports document that over 150 prepubertal and adult males have 
cryopreserved their testicular tissue or cells [91, 93-95, 100, 222-224] worldwide. Therefore, it is 
incumbent on the medical and research community to responsibly develop technologies 
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Figure 15. Standard and experimental options for preserving male fertility. 
    
 
 
 
 
 
 
 
 
 
 
Top, sperm obtained by ejaculation or surgical retrieval from the testes or epididymis are competent to fertilize 
oocytes using assisted reproductive techniques including intrauterine insemination (IUI), in vitro fertilization 
(IVF) or IVF with intracytoplasmic sperm injection (ICSI)) that are standard in most fertility clinics. These options 
are not available to prepubertal boys who are not producing sperm or to adult azoospermic men. Bottom, testis 
tissue obtained via biopsy from prepubertal boys contains SSCs that can produce sperm in the context of the intact 
tissue by xenotransplant, organ culture or autologous transplantation back into the individual (orange boxes). 
Sperm retrieved from cultured or transplanted tissue can be used for ICSI. Cells in suspension obtained from 
biopsied testicular tissue can be transplanted back into the endogenous seminiferous tubules of the patient (blue 
boxes). SSCs in the suspension can regenerate spermatogenesis and, in some cases, fertility. For infertile 
individuals who did not preserve germs cells before gonadotoxic therapy, induced pluripotent stem cells (IPSCs) 
may be produced from his somatic cells (e.g., skin or blood) to differentiate into transplantable germ cells (PGCs 
or SSCs) or haploid germ cells that can be used for ICSI (red boxes). Reprinted by permission from Macmillan 
Publishers Ltd: Clark AT, Phillips BT, Orwig KE, Nat Med. 2011 Dec 6;17(12):1564-5. 
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that will allow patients to use their tissue for reproductive purposes in the future. Our laboratory 
demonstrated previously that testicular tissue could be obtained from rhesus macaques by biopsy 
prior to the initiation of gonadotoxic therapy [86]. The testicular tissue (containing SSCs) was 
then digested with enzymes to produce a cell suspension that was cryopreserved. At a later date, 
cells were thawed and transplanted by ultrasound-guided rete testis injections into the testes of 
chemotherapy treated animals. The frozen and thawed cells engrafted recipient testes, 
regenerated spermatogenesis and produced functional sperm. Thus, clinical translation of the 
SSC transplantation technique appears to be on the horizon.  
To maximize the use of cryopreserved SSCs for future use, I investigated the colonization 
activity and UTF1 expression of cryopreserved intact testicular tissue pieces compared to 
cryopreserved cell suspension. Intact tissue pieces have the advantage that they can be used for 
tissue based or cell based approaches; whereas a cell suspension can only be used for cell culture 
or SSC transplantation. In case organ culture or testicular tissue grafts are a viable option to 
restore male fertility in the future, an optimal cryopreservation technique needs to be established.  
Slow-freezing is the preferred method for cryopreserving intact testicular tissue pieces in 
mice [225-227] and it has been validated with achieved live births using spermatozoa from the 
tissue grafts [225]. Some laboratories are also starting to cryopreserve intact human testicular 
tissue by slow-freezing [212, 224, 228, 229] as well as vitrification [230-232]. In both cases, 
differentiation of spermatogonia up to pachytene spermatocyte stage was observed in prepubertal 
testicular tissue after tissue grafting into nude mice [211, 212, 232].  
Slow-freezing and vitrification are both cryopreservation techniques that are designed to 
minimize damage by ice crystal formation within the cells. Slow-freezing involves cooling the 
cells at a low rate and as the temperature decreases, ice crystals form in the extra-cellular 
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solution [233, 234]. The concentration of cryoprotectant increases around the cells and that 
draws out the water from inside the cell, minimizing the formation of intracellular ice crystals in 
the cell cytoplasm. Slow cooling rates are necessary to allow enough time for the water to efflux 
from the cells.  Vitrification is a method of cryopreservation that uses higher concentrations of 
cryopreservation agent and faster cooling rates [235]. With this technique the transformation 
process from a liquid to a solid glass-like state happens rapidly without crystallization.   
It has been reported that both slow-freezing and vitrification do equally well at 
cryopreserving intact testicular tissue pieces [231, 232, 236-238] and maintain at least some 
functionality as demonstrated by tissue grafting experiments [212, 232]. Additionally, 
Pacchiarotti and colleagues compared slow-freezing of sexual reassignment patient testicular 
tissue to a cell suspension and showed that there is a trend that cryopreserving testicular tissue 
has a better viability and recovery of SSEA4 (undifferentiated spermatogonia marker) positive 
and VASA (germ cell marker) positive cells than cryopreserved cell suspension. The results in 
this study were not statistically significant [239] and spermatogonial  stem cell activity was not 
assessed.  
In this study, I compared cryopreservation efficiency of slow-frozen and thawed cell 
suspension to small (3-5 mm3) and large (6-10 mm3) intact tissue pieces with slow-freezing (SF) 
and vitrification. I hypothesized that the recovery of stem and progenitor spermatogonia is better 
from frozen and thawed cell suspension than from frozen and thawed intact testicular tissue 
pieces. In a cell suspension the distribution of cryopreservation media is uniform and all the cells 
are cryopreserved at a similar rate, compared to an intact piece of tissue, where I can only control 
the freezing rate and cryopreservation media concentration on the outside of the tissues [240]. 
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The experiments were analyzed by ICC staining for a marker of human stem and 
progenitor spermatogonia, UTF1, (see Figure 6) and also human-to-nude mouse 
xenotransplantation (see Section 1.4).  ICC for UTF1 revealed that cryopreserved intact tissue 
has more UTF1 positive cells per gram of tissue than cryopreserved cell suspension. Human to 
nude mouse xenotransplantation demonstrates that cryopreservation of intact pieces does at least 
as well as cryopreserving a cell suspension and slow-freezing small and large pieces of intact 
tissue  is significantly better than cryopreserving a cell suspension. 
3.2 MATERIALS AND METHODS 
Animals 
All experiments utilizing animals were approved by the Institutional Animal Care and 
Use Committees of the Magee-Womens Research Institute and the University of Pittsburgh and 
were performed in accordance with the National Institute of Health guidelines for the care and 
use of animals (assurance # A3654-01).  
 
Preparation of Human Testicular Tissue 
Normal adult human testicular tissue was obtained through the University of Pittsburgh 
Health Sciences Tissue Bank and Center for Organ Recovery and Education (CORE) under 
University of Pittsburgh IRB #0506140. Following the removal of tissue, it was transported to 
the laboratory on ice in Lactated Ringer’s solution. The tissue was either cut in to small pieces 
(3-5mm3) or large pieces (6-10mm3), or made into a cell suspension with a two-step enzymatic 
digestion described above (see section 2.2).  
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Controlled slow freezing and vitrification 
Testicular tissue was cryopreserved either as cell suspension or intact pieces of tissue. 
Cell suspension was cryopreserved using controlled slow freezing and intact pieces of tissue 
were cryopreserved with either controlled slow freezing (SF) or vitrification. For cell suspension, 
the vials were cooled at 1°C per minute in a -80°C freezer using Nalgene freezing containers 
(Nalgene-Nunc International) and then stored in liquid nitrogen. For slow freezing of intact 
pieces of tissue, 4-5 pieces of small tissue or 1-2 pieces of large tissue was put into 2.0ml 
cryovials containing 1.5ml of cryoprotectant medium consisting of 5%DMSO, 5% Serum 
Supplement Substitute (SSS) (Irvine Scientific) in Quinn’s Advantage Blastocyst (QAB) 
(SAGE) medium (as described in [224], except clinical grade media was used). The tissue was 
then equilibrated on ice for 30 minutes and then cooled using a programmable freezer as 
described before [224, 230]. The cooling rate was 1°Cmin-1 with holding at 0°C for 5 min, 
followed by cooling at 0.5°Cmin-1 until -8°C. At this temperature, the tissue was manually 
seeded and held for 10 min. The program continued to cool to -40°C at a rate of 0.5°Cmin-1, held 
for 10min and continued to -70°C at 7°Cmin-1, the cryovials were then plunged into liquid 
nitrogen. The tissue was thawed in 37°C water bath and washed in clinical grade PBS (Irvine 
Scientific). 
For vitrification of tissue pieces, the tissue was submerged into equilibration solution 
consisting of 7.5% DMSO, 7.5% ethylene glycol and 20% Dextran Serum Supplement (DSS, 
Irvine Scientific) in QAB medium for 10 minutes. The tissue was then transferred into 
vitrification solution consisting of 15% DMSO, 15% ethylene glycol, 20% DSS and 0.5M 
sucrose in QAB medium for 5 minutes (according to Vitrification Kit from Irvine Scientific). 
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The pieces were then placed in cryovials and stored in liquid nitrogen. Samples were thawed in 
pre-warmed (37°C) thawing solution consisting of 20% DSS and 1M sucrose in QAB medium 
for 5 minutes (Vitrification Kit; Irvine Scientific). They were then transferred into dilution 
solution consisting of 20% DSS and 0.5M sucrose in QAB medium for 5 minutes and finally 
washed in 20% DSS in QAB medium for 10 minutes, followed by two 5 minute washes.  
 
Human to nude mouse xenotransplantation 
Human to nude mouse xenotransplantations were done to analyze colonizing activity of 
putative human SSCs. All cryopreserved intact testicular tissue pieces were made into cell 
suspensions after thawing using a two–step enzymatic digestion with clinical grade enzymes, as 
described above in Preparation of Human Testicular Tissue (see section 2.2). Cell suspensions 
were transplanted into the testes of busulfan-treated (40 mg/kg; Sigma, at 5–6 weeks of age), 
immune-deficient nude mice (NCr nu/nu; Taconic, Germantown, NY) as described above (see 
section 2.2).   
 
Whole mount immunofluorescent quantification of human SSC colonizing activity in mouse 
seminiferous tubules 
Human to nude mouse xenotransplantation was analyzed by whole mount 
immunofluorescence. The testes were recovered 8 weeks following transplantation, the tunica 
was removed, and the intact seminiferous tubules were dispersed gently with Collagenase IV 
(1mg/mL) and DNase I (1mg/mL) in D-PBS. The tubules were fixed for 4 hours in 4% PFA and 
the whole mount immunofluorescence was carried out as described in section 2.2. 
Spermatogonial colonies were counted based on the following criteria: at least 4 cells exhibiting 
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spermatogonial morphology (ovoid shape with high nuclear to cytoplasmic ratio) and located on 
the basement membrane in a continuous area of recipient seminiferous tubule (≤100 µm between 
cells). 
 
Immunocytochemistry 
Frozen and thawed cells were spotted on Superfrost slides and fixed with methanol. The 
cells were then rehydrated with D-PBS and blocked with a buffer containing 3% bovine serum 
albumin and 5% normal goat serum in order to reduce nonspecific binding. Rabbit anti- UTF1 
(1:500; MAB4337, Millipore) antibody was added to the cells and incubated for 90 min at room 
temperature. Isotype matched normal IgG was used as negative control. Primary antibody was 
detected using goat anti-rabbit AlexaFluor-488 conjugated secondary antibody (1:200, 
Invitrogen). The slides were mounted with VectaShield (Vector Laboratories) mounting medium 
containing DAPI for detection of all nuclei and the staining was observed with a Nikon Eclipse 
E600 Fluorescence microscope and images captured with MetaView Digital Imaging software.  
 
Statistical analysis  
I present descriptive statistics (mean, standard deviation, min, median, and max) of the 
number of colonies per gram of tissue and UTF1 positive cells per gram of tissue for each of the 
five groups (frozen thawed cell suspension, vitrified large tissue pieces, vitrified small tissue 
pieces, slow-freezing large tissue pieces and slow-freezing small tissue pieces).  The number of 
colonies per gram of tissue and the number of UTF1 positive cells per gram of tissue were 
compared between groups using the Dwass, Steel, Critchlow-Fligner (DSCF) multiple 
comparison analysis, which is based on pairwise two-sample Wilcoxon rank sum comparisons.  I 
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chose this technique instead of parametric analysis of variance (ANOVA) because the skewed 
distribution of colonies per gram of tissue violates the assumptions required for proper 
application of ANOVA, necessitating the use of a non-parametric test.  The DSCF analysis 
compares the median dependent variable in each possible combination of the five groups (frozen 
thawed cell suspension, vitrified large tissue pieces, vitrified small tissue pieces, slow-freezing 
large tissue pieces and slow-freezing small tissue pieces).  The DSCF test is an extension of the 
standard Wilcoxon rank-sum test, but adjusts for pairwise comparisons of multiple groups.  
Within this test, a statistically significant result for any particular comparison (i.e. slow-freezing 
small tissue pieces vs. frozen thawed cell suspension) indicates that the center of the distribution 
of the dependent variable in one group differs significantly from the center of the distribution in 
the other group (i.e. that the median number of colonies per gram of tissue in slow-frezing small 
tissue pieces is significantly greater than the median number of colonies per gram of tissue in 
frozen thawed cell suspension). 
3.3 RESULTS 
3.3.1 Acquisition of human testicular tissue 
All the tissue used in the experiments came from 5 organ donors between the ages 15-49. The 
testis weight ranged from 8.5 to 23.9 g (after pathology) and yielded 44.7x106±5.8x106 cells per 
gram of tissue. The tissues were cryopreserved between 1 and 1.5 month before performing the 
experiments.  
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3.3.2 UTF1 staining of cryopreserved cells and tissues 
Human testicular tissue was cryopreserved with slow-freezing (SF) as a cell suspension and as 
small and large intact pieces of tissue. Testicular tissue pieces (small and large), were also 
cryopreserved by vitrification (Table 1). At a later date, the cells and tissues were thawed and all 
the intact pieces of tissues were made into cell suspensions. The cell suspensions from each 
group were stained for UTF1 (spermatogonia marker, see Figure 6) by immunocytochemistry.  
Table 1. Descriptive statistics for UTF1 positive cells per gram of tissue for human testicular cell and 
tissue cryopreservation. 
 
The results were normalized to UTF1 positive cells per gram of tissue frozen. The median UTF1 
positive cells per gram of tissue was highest in the SF large tissue piece samples (median=8.6, 
range [0-77]) and SF small tissue piece samples (median=6.9, range [0.003-43.4]) (Table 1 and 
Figure 16). These were significantly greater than the median UTF1 positive cells per gram of 
tissue in the frozen thawed cell suspension group (median=1.1, range [0.11-3.9], P < 0.0001), 
vitrified large tissue pieces group (median=3.7, range [0-17.1], P < 0.01), and the vitrified small 
 Mean SD Min Median Max 
Frozen thawed 
cell suspension 
1.47 1.11 0.11 1.1 3.9 
Vitrified large 
tissue pieces 
4.4 3.6 0 3.7 17.1 
Vitrified small 
tissue pieces 
5.4 7.2 0 2.9 32.9 
Slow-freezing 
large tissue 
pieces 
14.9 16.9 0 8.6 77.2 
Slow-freezing 
small tissue 
pieces 
10.4 9.9 0.003 6.9 43.4 
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tissue pieces group (median=2.9, range [0-32.9], P < 0.01). Recovery of the UTF1 positive cells 
in the SF large tissue pieces group was not significantly different than the SF small tissue piece 
group (P = 0.7712).   
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Figure 16. ICC for UTF1 of cryopreserved human testicular cells and tissue pieces. 
  
 
 
 
 
 
 
 
Similar to the SF small and large tissue pieces, recovery of UTF1 positive cells was 
significantly greater from vitrified small and large tissue pieces than from the frozen thawed cell 
suspension (P = 0.0119 and P < 0.0001, respectively) (Table 1 and Figure 16). 
3.3.3 Colonizing activity in cryopreserved cells and tissues 
The results from UTF1 staining of cryopreserved cells and tissues were confirmed by human-to-
nude mouse xenotransplantation experiments. The cryopreserved cell suspension and intact 
tissue pieces were thawed and the intact tissue pieces were made into a cell suspension before 
xenotransplantation into nude mice. The median number of colonies per gram of tissue frozen 
was highest in the SF small tissue piece samples (median=426.3, range [0-3209]) (Table 2 and 
Figure 17). This was significantly greater than the median number of colonies per gram of tissue 
in the frozen thawed cell suspension group (median=28.0, range [0-185], P = 0.0003), vitrified 
large tissue piece group (median=0, range [0-420], P < 0.0001), and the vitrified small tissue 
piece group (median=17.9, range [0-1941], P = 0.0472). Colonies per gram of tissue in the SF 
Human testicular cells and tissue pieces were cryopreserved and thawed. All the tissue pieces were made into a 
cell suspension after thawing and all groups were stained with UTF1. (A) Slow-freeze (SF) large and SF small 
tissue pieces have significantly higher UTF1 positive cells per gram of tissue than other groups. Different letter 
indicate P < 0.05, same letters indicate P > 0.05. Black line in the brown box indicates median, the bottom of the 
brown box is quartile 1(Q1), the top is quartile 3 (Q3). The top error bar indicates max and bottom error bar 
indicates minimum. (B-F) Representative images of UTF1 staining from each sorted fraction and unsorted cells. 
At least 10 views were counted from each fraction based on DAPI staining and UTF1 staining. N=5. Scale bar = 
50 µm.  
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small tissue piece group was not significantly different was the SF large tissue piece group 
(median=375.9, range [0-2243], P = 0.9960).  
 
Table 2. Descriptive statistics for xenotransplant colonies per gram of tissue for human testicular cell 
and tissue piece cryopreservation 
 
 Mean SD Min Median Max 
Frozen thawed 
cells 
49.6 52.8 0 28.0 185.2 
Vitrified large 
tissue pieces 
48.0 108.8 0 0 420.6 
Vitrified small 
tissue pieces 
370.3 661.5 0 17.9 1941.1 
Slow-freezing 
large tissue 
pieces 
487.3 501.9 0 375.9 2243.9 
Slow-freezing 
small tissue 
pieces 
760.2 922.1 0 426.3 3209.1 
 
 
SF large tissue piece group was also significantly greater than frozen thawed cell 
suspension (P < 0.0001), vitrified large tissue piece group (P < 0.0001), and borderline 
significant compared to vitrified small tissue piece group (P = 0.0528). Colonizing activity in the 
frozen thawed cell suspension, vitrified large tissue pieces, and vitrified small tissue pieces 
groups were not significantly different (Table 2 and Figure 17). 
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Figure 17. Colonization of cryopreserved human testicular cells and tissue pieces. 
  
 
 
 
 
 
3.4 DISCUSSION 
Spermatogonial stem cells are the adult tissue stem cells of the testes that may have the 
potential to treat some cases of male infertility. For example, the SSC freezing and 
transplantation methods could be used to preserve and restore fertility of prepubertal boys who 
Human testicular cells and tissue pieces were cryopreserved and thawed. All the tissue pieces were made into a 
cell suspension after thawing and all groups were transplanted into nude mouse testis. (Inset) Two months after 
transplant, colonies of human spermatogonia were identified in whole mount preparations of recipient mouse 
seminiferous tubules using the rabbit anti-primate antibody. Colonies in each recipient testis were counted and 
normalized to colonies per gram of frozen tissue. Different letter indicate P < 0.05, same letters indicate P > 0.05. 
Black line in the brown box indicates median, the bottom of the brown box is quartile 1(Q1), the top is quartile 3 
(Q3). The top error bar indicates max and bottom error bar indicates minimum. N = 5. Scale bar = 100 µm. 
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are undergoing chemotherapy or radiation for cancer or other conditions that may render them 
infertile. These boys do not make sperm yet, so they do not have the option to cryopreserve a 
semen sample. Currently, there are several stem cell based techniques in the research pipeline 
that may in the future offer opportunities for these prepubertal patient to have their own 
genetically related children (Figure 15, bottom). These techniques are still experimental, but 
several centers around the world are cryopreserving testicular tissues from prepubertal boys 
because it is anticipated that stem cell therapies will be available in the future [91, 93-95, 100, 
222-224]. Methods currently in the research pipeline include SSC transplantation [70, 73-85, 90], 
testicular tissue grafting [207-212, 241-247], testicular organ culture [213, 214]  and induced 
pluripotent stem cell (iPSC) technologies [215-221]. Because it is uncertain which of the fertility 
preservation/restoration technique(s) will be translated to the clinics in the future, it is important 
to preserve tissues in a way that will maximize access to downstream applications. Many studies 
have demonstrated that testicular cell suspensions can be frozen, thawed and transplanted to 
regenerate spermatogenesis [70, 72, 73, 86, 122, 248-252]. However, freezing testicular tissues 
as cell suspension eliminates the possibility of using testicular tissue grafting or organ culture to 
produce sperm. Some laboratories are cryopreserving patient tissues as intact tissue pieces and 
have shown that this method cryopreserves the SSCs for testicular tissue grafting in mice [212, 
232]. Therefore, to maximize the potential use of the cryopreserved prepubertal patient tissues in 
the future, I wanted to test whether cryopreserving intact pieces of tissue will compromise the 
SSC activity for SSC transplantation technique.   
Here, I evaluated the recovery of stem and progenitor spermatogonia from human 
testicular tissue frozen as a cell suspension versus pieces of intact tissue. The intact tissue pieces 
were cryopreserved either by slow-freezing or vitrification. Slow-freezing has been used to 
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successfully cryopreserve rodent testicular tissue [225-227] and human testicular tissue for 
xenografting purposes [230-232]. Vitrification is a technique that is used in oocyte and embryo 
cryopreservation [253, 254]. Vitrification and slow-freezing are both techniques that minimize 
ice crystal formation and therefore prevent cell damage [233, 234]. Vitrification uses higher 
cryopreservative concentration and faster cooling rates to eliminate ice crystal formation in the 
intracellular and extracellular space [234, 235]. Slow-freezing uses a slow cooling rate to allow 
water to exit the cell to minimize intracellular ice crystal formation [234]. Vitrification has the 
advantage that it does not require expensive freezing machines and can be performed fast in 
almost any clinical laboratory.  
I hypothesized that the recovery of stem and progenitor spermatogonia is more efficient 
from frozen and thawed cell suspension than from frozen and thawed intact pieces of tissue. I 
analyzed the cryopreservation conditions with ICC for UTF1 (spermatogonia maker, Figure 6) 
for a quick readout assay and also confirmed the results by human-to-nude mouse 
xenotransplantation assay. I found that all freezing conditions for intact pieces of tissues were at 
least as effective, if not more effective than slow-freezing a cell suspension (Figures 16 and 17). 
To our surprise, the recovery of stem and progenitor spermatogonia from slow-frozen small or 
large pieces of intact tissues was significantly better than slow-freezing a cell suspension. 
Recovery of UTF1 positive cells from vitrified small and large pieces of testicular tissue pieces 
was also significantly better than frozen thawed cell suspension, but not as good as from slow-
frozen tissue pieces. Colonization activity in xenotransplants assay between vitrified tissue 
pieces and frozen thawed cell suspension was not statistically significant, the reason for that 
could be high variability within each sample. The variability is due to variation between different 
human samples. Cryopreserving a cell suspension requires more processing steps before (cell 
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digestion, washing, centrifugation) and after freezing (washes to remove cryoprotectant) than 
cryopreserving intact tissue pieces.  The additional processing steps may reduce the recovery of 
stem and progenitor spermatogonia.  
 Vitrification of intact testicular tissue has been shown to be at least as effective as slow-
freezing in some cases [231, 232, 236-238] but that was not the case here. One of the reasons 
could be that the functional endpoint in some of these studies was grafting of the cryopreserved 
tissue into nude mice. In tissue grafting, the SSCs remain in their niche, compared to SSC 
transplantation, where the tissue is made into a cell suspension. This difference could explain 
why one method works better for SSC transplantation than the other. It could also be that there 
are small differences in the technique between laboratories. In any case, it is advantageous to 
cryopreserve prepubertal patient testicular biopsies as intact pieces of tissues so that the potential 
to use it for different techniques is maximized.  
These studies were conducted using human tissues and the same clinical grade reagents 
that one used to process patient testicular tissues in our fertility preservation center. Therefore 
the results can be immediately implemented in protocols for processing patient tissues. 
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4.0  ELIMINATING MALIGNANT CONTAMINATION FROM THERAUPEUTIC 
HUMAN SPERMATOGONIAL STEM CELLS 
4.1 INTRODUCTION 
Over 12,000 children are diagnosed with cancer every year in the US, and it has been estimated 
that a male infant has a 1 in 300 chance of being diagnosed with a malignancy by the age of 20 
[255]. Fortunately, success rates in treating childhood cancer have increased dramatically over 
the past few decades, and now over 80% of children survive following treatment [256, 257]. 
Given this growing cohort of adult survivors of childhood cancers, emphasis is now being placed 
on quality of life issues following successful treatment. Many therapies to treat cancer are 
gonadotoxic and can lead to infertility, and fertility potential has an important impact on quality 
of life according to cancer survivors [57, 258-260]. In fact, the American Society of Clinical 
Oncology [57] and American Society of Reproductive Medicine  [58] now recommend that the 
reproductive risks of cancer therapies and fertility preservation options should be routinely 
discussed with patients before beginning treatment. 
In men, freezing semen samples is an efficient and well-established technique to preserve 
fertility for those facing gonadotoxic treatments, such as chemotherapy or radiation. 
Unfortunately, this is not an option for boys who have not yet entered puberty and do not have 
sperm. However, these boys do have spermatogonial stem cells (SSCs) in their testes that are 
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poised to produce spermatogenesis at the start of puberty [7, 95, 224]. SSCs maintain 
spermatogenesis throughout postpubertal life, and they are defined by their ability to undergo 
both self-renewing cell divisions and differentiation, leading to the production of haploid sperm. 
Brinster and colleagues provided the initial demonstration that testicular cells from a fertile 
mouse could be transplanted into the seminiferous tubules of an infertile recipient, in which they 
produced complete spermatogenesis and sometimes restored fertility [68-73]. Regeneration of 
spermatogenesis following SSC transplantation has now been established in several animal 
models, including rodents, goats, sheep, pigs, dogs, and monkeys [70, 72, 73, 86, 122, 248-252]. 
The potential of using SSCs to preserve and restore fertility in patients receiving 
gonadotoxic therapies has been extensively discussed [94, 222, 261-268]. In theory, testicular 
cells obtained via biopsy prior to cancer treatment could be cryopreserved and then 
retransplanted following clinical remission. Several centers around the world, including our own 
Fertility Preservation Program in Pittsburgh (http://www.mwrif.org/220), are now performing 
testicular biopsies on boys prior to the initiation of cancer therapy in hopes that this tissue can be 
used in the future to restore fertility [95, 222, 224, 267]. However, to make SSC transplantation a 
realistic clinical option for the prepubertal patient cohort, two major hurdles must be overcome. 
First, we need to learn the characteristics of human SSCs to facilitate their isolation and 
enrichment. Second, techniques to remove malignant contamination from the testis cell 
suspension are needed to eliminate the risk of reintroducing cancer back into survivors. 
Unfortunately, there is a real potential for malignant contamination in testicular tissue 
obtained from patients prior to cancer treatment, especially for those with hematologic cancers. 
One study demonstrated that 20% of boys with acute lymphocytic leukemia possessed malignant 
cells in a testicular biopsy taken prior to the initiation of chemotherapy [269]. Furthermore, it has 
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been demonstrated in a rat model of leukemia that transplantation of testicular cells from 
leukemic donors consistently transmitted leukemia to healthy recipients [270]. Fujita and 
colleagues were the first to demonstrate that FACS could be used to successfully remove 
malignant cells from a testicular sample prior to SSC transplantation [262]. They used antibodies 
directed against cell surface antigens CD45 and MHC class I (HLA-ABC) to remove the 
malignant cells from testis cell suspension. Sorted and unsorted cell suspensions were then 
transplanted into the seminiferous tubules of infertile recipient mice. In this landmark study, 
recipient mice that received transplants with unsorted cells consistently developed leukemia, 
whereas those transplanted with sorted cells did not. Additionally, viable offspring were 
generated from the infertile recipients following transplantation of the sorted germ cells [262]. 
Fujita and colleagues followed up this initial report by demonstrating that 7 out of 8 human 
leukemic cell lines also expressed the cell surface antigens CD45 and MHC class I, and thus 
these leukemic markers could theoretically be used to separate leukemic cells from testicular 
cells in humans as well, but this was not assessed experimentally in that study and transplants 
were not performed [263]. Hermann and coworkers demonstrated the feasibility of removing 
contaminating leukemic cells from nonhuman primate testis cell suspensions by FACS sorting 
with THY1 (spermatogonial marker) and CD45 (leukemia marker) but also did not perform 
transplants to assess malignant potential [159]. 
However, not all studies using immune-based sorting technologies to separate malignant 
cells from testicular cell suspensions have been as successful [185, 264]. Using a leukemic rat 
model, Hou and colleagues concluded that a single marker sort is generally not adequate to 
remove malignant contamination [185]. Moreover, studies using human tissue to assess 
decontamination methods have been very limited to date, likely due to difficulties in obtaining 
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such material for research. However, human studies are needed to demonstrate feasibility and 
safety before SSC transplantation can be translated to the clinic. 
In this chapter, I characterized the cell surface phenotype of human spermatogonia in 
testicular tissue obtained from organ donors as well as the MOLT-4 leukemic cell line derived 
from a patient with acute T cell lymphoblastic leukemia. I used this information to devise sorting 
strategies to isolate and enrich human SSCs and to remove malignant contamination from human 
testicular cell suspensions that had been “spiked” with MOLT-4 leukemia cells. A human-to-
nude mouse xenotransplantation biological assay was used to assess SSC activity and malignant 
contamination in fractions obtained from FACS of MOLT-4-contaminated human testis cell 
suspensions. 
4.2 MATERIALS AND METHODS 
Animals 
All experiments using animals were approved by the Institutional Animal Care and Use 
Committees of the Magee-Womens Research Institute and the University of Pittsburgh and 
performed in accordance with the NIH guidelines for the care and use of animals (assurance no. 
A3654-01). 
Procurement and processing of human testicular tissue. 
Deidentified human testicular tissue was obtained through the Center for Organ Recovery 
and Education and the University of Pittsburgh Health Sciences Tissue Bank under University of 
Pittsburgh IRB no. 0506140. Tissue was obtained from postpubertal male organ donors and 
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transported on ice in Lactated Ringer’s solution following procurement. The time of tissue 
processing ranged from 7 to 21 hours following organ procurement. A single cell suspension of 
human testicular parenchyma was prepared with two step enzymatic digestion as described in 
Chapter 2. 
 
MOLT-4 cell line culture 
The MOLT-4 cell line, derived from a 19-year-old man with acute T cell lymphoblastic 
leukemia in relapse [271], was obtained from American Type Culture Collection (ATCC). 
Cultures were established in RPMI-1640 media (GIBCO, Invitrogen) with 10% FBS and 
supplemented with antibiotic-antimycotic solution containing penicillin, streptomycin, and 
amphotericin (Antibiotic-Antimycotic, GIBCO Cell Culture, Invitrogen). Fresh media was added 
every 2 to 3 days, and cells were subcultured at or before they reached a density of 2 × 
106 cells/ml, as per manufacturer recommendations. 
Flow cytometry 
Flow cytometry was used to characterize the expression of a panel of cell surface 
antigens on MOLT-4 and human testicular cells. To assess antigen expression, 0.5 × 106 cells 
were stained with fluorophore-conjugated primary antibodies for 20 minutes on ice. Cells were 
also stained with isotype control antibodies to correct for nonspecific antibody binding. 
Preliminary titration experiments were carried out with each antibody to determine the optimal 
antibody concentration for both MOLT-4 cells and human testicular cells. Following staining, 
cells were washed 3 times with cold Dulbecco’s PBS (D-PBS; GIBCO, Invitrogen) containing 
10% FBS. A FACSDiva (Becton Dickinson) machine was used to perform flow cytometry, and 
the percentage of cells expressing the antigen of interest was determined by quantifying the 
 71 
percentage of cells with higher fluorescence intensity than the isotype control. Each experiment 
was replicated 3–5 times. 
Fluorescence-activated cell sorting 
Based on flow cytometry results, markers that were expressed on >95% of MOLT-4 cells 
were considered markers of MOLT-4 leukemia cells. In contrast, markers expressed by <1% of 
MOLT-4 cells and 5% or more of human testis cells were considered potential SSC markers. 
CD49e (α5 integrin) and HLA-ABC were expressed by >95% of MOLT-4 cells and therefore 
met the criteria for potential MOLT-4 markers. EPCAM was expressed by <1% of MOLT-4 
cells and 5% or more of human testis cells and met the criteria for a potential SSC marker. These 
markers were selected for further analysis by FACS and immunocytochemical analysis of human 
testis cell fractions. 
Human testis cell suspensions were stained with fluorescent-conjugated antibodies (anti-
human CD49e clone NKI-SAM-1, BioLegend; anti-human HLA-ABC clone G46-2.6, BD 
Biosciences; anti-human EPCAM clone 9C4, BioLegend) and sorted using FACSvantage SE 
fluorescence-activated cell sorter (Becton Dickinson) as described in Chapter 2.  
Immunocytochemistry  
Cell fractions were collected in Opti-MEM (GIBCO, Invitrogen) supplemented with 10% 
FBS, spotted onto slides (Superfrost Plus; Fisher Scientific), and fixed with methanol. The slides 
were stained as described in Chapter 2 with rabbit anti–SALL4 (1:500, Abcam). To quantify the 
percentage of cells expressing SALL4 in each sorted fraction, at least 10 random images of each 
fraction were recorded and the number of SALL4 positive cells as well as the total number of 
cells was quantified. An unsorted sample of testicular cells was also stained to determine the 
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percentage of unsorted testicular cells that express SALL4. These experiments were replicated 3 
times for each representative antibody (HLA-ABC, CD49e, and EPCAM) using testicular tissue 
from different male donors. 
Xenotransplantation and whole mount immunofluorescent quantification of colonization activity 
of undifferentiated spermatogonia  
Following FACS, unsorted and sorted testicular cell fractions were transplanted into the 
testes of busulfan-treated, immune-deficient nude mice (NCr nu/nu; Taconic) as previously 
described in Chapter 2. For experiments involving FACS of contaminated testicular cell 
suspensions, MOLT-4 cells were mixed with human testicular cells such that MOLT-4 cells 
made up approximately 10% of the final cell suspension prior to sorting. The concentration of 
cells transplanted into seminiferous tubules from each fraction varied based on the total number 
of cells collected following sorting. An average of 996,845 cells were transplanted per recipient 
mouse testis from the unsorted spiked cell suspension, 63,780 cells were transplanted from the 
EPCAM dim/CD49e negative/HLA-ABC negative (spermatogonial) fraction, and 5,000 cells 
were transplanted from the EPCAM negative/CD49e positive/HLA-ABC positive (MOLT-4) 
fraction. A prior sensitivity analysis demonstrated that as few as 10 MOLT-4 cells were capable 
of inducing tumor formation when transplanted into the testes of immunodeficient mice treated 
with busulfan, and injection of 1,000 MOLT-4 cells reliably induced tumor formation in the 
majority of mice (83%) [159]. This experiment was designed primarily to assess SSC activity in 
each fraction. Malignant contamination of each fraction was also evaluated by injection into the 
testicular interstitial space, which is an excellent environment for tumor formation (see Human-
to–nude mouse tumor bioassay below). 
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Human-to–nude mouse tumor bioassay  
In addition to the intratubular transplant bioassay for human spermatogonia, 
xenotransplants into the interstitial space (between seminiferous tubules) of nude mouse testes 
were performed to assess tumorigenic potential of unsorted and sorted cell fractions. I found that 
the interstitial space was more conducive to tumor formation than the intratubular space and was 
therefore a more sensitive bioassay for malignant contamination. Approximately 10 μl of cell 
suspension was transplanted into the interstitial space at cell concentrations of 0.5 × 106 cells/ml 
to 5 × 106 cells/ml (50,000 cells per recipient mouse testis in the unsorted spiked arm, 5,000 cells 
per testis in all other experimental arms) by initially cannulating the efferent duct and then 
advancing the needle through the rete testis into the interstitial space. As indicated above, as few 
as 10 MOLT-4 cells are sufficient to produce tumors following transplantation into the testes of 
nude mice [159]. Therefore, the human-to–nude mouse tumor assay has the sensitivity to detect a 
0.2% contamination with cancer cells (10 cells in a transplanted fraction of 5,000 cells). 
Following interstitial transplantation, the mice were monitored and palpated regularly to assess 
for tumor formation and sacrificed for analysis when palpable tumors were present or by 4 
months following transplantation. The testes were removed and examined grossly for tumor 
formation. 
 
TF-1a lymphoblastic leukemia cell line: marking with GFP, phenotyping and sorting 
 
To determine if the multi-parameter FACS approach would be successful across different 
human malignancies, another human leukemic cell line, TF-1a was used in a second spiked 
sorting experiment. TF-1a, a lymphoblastic cell line derived from a 35 year old Japanese male 
with erythroblastic leukemia was obtained from ATCC [272]. 
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Previous sensitivity analyses had demonstrated that TF-1a cells do not form solid tumors 
as consistently as MOLT-4 cells when transplanted into the testes of immune-deficient nude 
mice. Thus, TF-1a cells were transduced with a lentivirus containing GFP driven by the 
ubiquitin-C promoter (generously provided by Dr. Carlos Lois, University of Massachusetts 
[273]) to enable tracking of malignant cells through the multi-parameter FACS experiments. The 
cell culture was then expanded and cloned by limiting dilution. Cells derived from a single GFP-
expressing clone, TF-1a (C2), were used for all experiments in this study. Cultures were 
established in RPMI-1640 media (GIBCO, Invitrogen) with 10% FBS and supplemented with 
Antibiotic-Antimycotic solution containing penicillin, streptomycin, and amphotericin (GIBCO 
Invitrogen Cell Culture). Fresh media was added every 2-3 days and cells were passaged at or 
before they reached a density of 2 x 106 cells/mL as per manufacturer recommendations. 
Initial flow cytometry experiments using the TF-1a-GFP clone demonstrated that over 
>95% of cells expressed the markers CD45 and CD49e, but not HLA-ABC (as I had observed 
for the MOLT-4 leukemic cells). Additionally, EPCAM was expressed on <1% of the TF-1a 
cells. Thus, our multi-parameter sorting approach with TF-1a utilized CD45-PE and CD49e-PE 
as markers for TF-1a leukemic cells, and EPCAM-APC as a marker of spermatogonia. Spiked 
sorting experiments were carried out as described above by adding TF-1a-GFP cells to a 
suspension of human testicular cells and performing multi-parameter FACS. 
 
Immunohistochemistry of testicular tumors with NuMA 
 
To demonstrate that the testicular tumors observed after transplantation of MOLT-4 cells 
and the EPCAM-/CD49e+/HLA-ABC+ fraction resulted from the MOLT-4 cells injected and are 
of human origin, immunohistochemistry was performed with a human-specific polyclonal 
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antibody directed against the nuclear mitosis apparatus protein (NuMA), a protein involved in 
the formation and maintenance of the mitotic spindle. To accomplish this, the tumors were fixed 
with 4% paraformaldehyde overnight, paraffin-embedded and sectioned (5 μm). The tissues were 
then stained as in Chapter 2.2 using anti-NuMA antibody (1:100, Abcam, Cambridge, MA).  
Statistics  
Analysis of variance on nested linear mixed-effect models was used to compare 
differences among the percentage of SALL4 positive cells in unsorted versus sorted cell fractions 
in the immunohistochemistry experiments and colonizing activity in the human-to–nude mouse 
xenotransplant bioassay. P values of less than 0.05 were considered significant. 
4.3 RESULTS 
4.3.1 Surface antigen expression on human testicular cells and MOLT-4 lymphoblastic 
leukemia cells.  
To characterize cell surface antigens on human testicular cells and MOLT-4 acute lymphoblastic 
leukemia cells [271], respectively, flow cytometry was performed for a panel of 24 markers, 15 
of which exhibited positive immunoreactivity with human testis cells and/or MOLT-4 leukemic 
cells (Table 3). Our aim with this set of experiments was to characterize the cell surface 
phenotypes of human spermatogonia and human MOLT-4 leukemia cells to identify antigens 
that could be used to distinguish these 2 cell populations. For MOLT-4 markers, I selected  
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Table 3. Expression pattern of various cell surface antigens on MOLT-4 lymphoblastic leukemia cells 
and human testicular cell suspensions (expressed in percentage)    
Cell surface antigen MOLT-4 Human testis 
CD4 75.9 ± 13.5 0.14 ± 0.02 
CD9 68.9 ± 6.0 16.1 ± 0.4 
CD24 0.17 ± 0.07 2.46 ± 0.3 
ΙΤGΒ1 (CD29) 98.3 ± 0.5 24.4 ± 3.7 
CD31 (PECAM-1) 51.8 ± 2.3 1.1 ± 0.3 
CD34 4.5 ± 1.7 15.96 ± 1.1 
CD45 97.9 ± 0.9 3.56 ± 0.6 
ΙΤGΑ5 (CD49e) 97.6 ± 0.9 23.2 ± 4.2 
ITGA6 (CD49f) 12.5 ± 1.7 53.2 ± 8.7 
CD54 56.1 ± 7.7 26.1 ± 3.5 
CD71 91.6 ± 1.0 0.46 ± 0.2 
THY1 (CD90) 2.2 ± 0.5 21.1 ± 1.3 
CD147 98.3 ± 0.5 53.1 ± 14.6 
EPCAM (CD326) 0.1 ± 0.0 16.4 ± 3.9 
HLA-ABC 96.9 ± 1.2 9.42 ± 0.7 
 
antigens that were expressed on greater than 95% of MOLT-4 cells for further study. CD29, 
CD45, CD49e, CD147, and HLA-ABC met these criteria (Table 3), and HLA-ABC, CD49e, and 
CD147 were selected for use in subsequent experiments. To identify potential spermatogonial 
markers that were distinct from MOLT-4 cells, our goal was to identify antigens that were 
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expressed by less than 1% of MOLT-4 cells and by 5% or more of human testis cells. ITGA6 
(CD49f), THY1 (CD90), and EPCAM (CD326) were of particular interest because these markers 
are expressed by human spermatogonia (see Chapter 2). ITGΒ1 (CD29) has been demonstrated 
to be expressed on spermatogonia in other animal models [20, 29, 185, 263]. ITGA6, ΙΤGB1, 
and THY1 were rejected for further consideration, because they were expressed by >1% of 
MOLT-4 cells. EPCAM satisfied the criteria (expressed on 0.1% of MOLT-4 cells and 16.4% of 
human testis cells; see Table 3) and was selected for further study. 
 
4.3.2 Expression of HLA-ABC and CD49e in adult human testicular cell suspension 
FACS experiments were performed to determine whether putative MOLT-4 markers CD49e, 
HLA-ABC, and CD147 (expressed by >95% of MOLT-4 cells) were also expressed by SALL4 
positive spermatogonia in human testis cell suspensions. The goal of these experiments was to 
identify markers that can distinguish MOLT-4 leukemia cells from human spermatogonia. FACS 
analysis of human testis cells for HLA-ABC (Figure 18A), followed by immunocytochemistry of 
positive and negative fractions for SALL4 (Figure 18B–E), revealed that the majority of SALL4 
positive human spermatogonia were recovered in the HLA-ABC–negative fraction (P < 0.0001). 
Similarly, the majority of SALL4 positive spermatogonia were recovered in the CD49e-negative 
fraction of human testis cells (P < 0.0001; Figure 18F–J). SALL4 positive spermatogonia were 
found in both the CD147-positive and -negative fractions (data not shown), and, thus, the CD147 
marker was not deemed useful for separating MOLT-4 cells from spermatogonia. 
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 Figure 18. SALL4–positive human spermatogonia do not express HLA-ABC or CD49e. 
 
 
 
 
 
 
 
 
 
4.3.3 Analysis of FACS sorted fraction for human spermatogonia  
Human testicular cell suspensions were contaminated with 10% MOLT-4 cells to simulate a 
clinical situation in which a patient preserves a testicular biopsy that contains SSCs and might be 
used in the future to restore fertility (i.e., by SSC transplantation). To safely use the preserved 
tissue for autologous transplantation, the malignant cells must be identified and completely 
removed. The objectives of this set of experiments were to determine (a) whether spermatogonia 
could be successfully sorted from a contaminated testicular cell population, (b) whether 
spermatogonia could be enriched, and (c) whether contaminating malignant cells could 
successfully be separated from spermatogonia. To achieve these goals, I sorted the contaminated 
human testis cell suspension into fractions based on relative expression of EPCAM 
(spermatogonial marker) as well as CD49e and HLA-ABC (MOLT-4 markers). As shown in 
Figure 19  populations of cells were gated: EPCAM–/CD49e–/HLA-ABC– (fraction I); EPCAM–
 (A) To determine whether human spermatogonia express HLA-ABC, human testicular cell suspensions were 
stained with APC-conjugated HLA-ABC antibodies and sorted into positive and negative fractions by FACS. 
Negative gates were defined by analysis of human testis cells using APC-conjugated isotype control antibodies. 
(B–E) Following FACS, each fraction of cells was fixed and immunocytochemistry was performed to assess 
SALL4 expression; then, fractions were counterstained with DAPI to quantify total cells. (B) The percentage of 
cells in each unsorted and sorted fraction that displayed SALL4 staining (SALL4 positive green cells/DAPI-
stained total cells). (F–J) A similar experiment was conducted using APC-conjugated CD49e antibodies. Scale 
bar: 50 μm (C–E and H–J). Bars in B and G indicate the mean percentage of SALL4–positive cells (SALL4–
positive cells/total cells) in each fraction. Error bars in B and G represent SEM from 3 replicate sorting 
experiments. *P < 0.001, compared with unsorted cells. Reprinted with permission from Dovey SL and Valli H et 
al., J Clin Invest. 2013 Apr 1;123(4):1833-43, Copyright (2014). 
 
 80 
/CD49e+/HLA-ABC+ (fraction II); EPCAM+/CD49e–/HLA-ABC– (fraction III); and 
EPCAM+/CD49e+/HLA-ABC+ (fraction IV). The EPCAM+/CD49e–/HLA-ABC– fraction (III) 
was further fractionated based on level of EPCAM expression and side scatter of incident light 
(Figure 19B, fractions IIIa and IIIb) into EPCAMdim/SSchigh (Figure 19A, fraction III, green) and 
EPCAMbright/SSclow (Figure 19A, fraction III, blue). Based on data in Figures 13 and 18 and 
Table 3, I hypothesized that human spermatogonia would be recovered in fraction IIIa (Figure 
19A and B, green) and that MOLT-4 cells would be recovered in fraction II (Figure 19A, red). 
As expected, immunocytochemical staining of sorted fractions revealed significant 
enrichment of SALL4 positive cells in the EPCAMdim/SSchi/CD49e–/HLA-ABC– fraction (IIIa) 
compared with unsorted testicular cells (33.9 ± 1.0% vs. 4.5 ± 0.6% SALL4 positive cells in the 
unsorted population, P = 0.0005; Figure 19C–F). This fraction will be described as 
EPCAMdim/CD49e–/HLA-ABC– from this point forward and in Figures 19 and 20. No SALL4 
positive cells were found in the EPCAM–/CD49e+/HLA-ABC+ fraction (II) (Figure 19E and F). 
Furthermore, the xenotransplantation analysis of spermatogonial colonies in the seminiferous 
tubules of nude mice confirmed that colonization activity was enriched in the 
EPCAMdim/CD49e–/HLA-ABC– fraction compared with unsorted (unspiked) testicular cells (133 
± 25.2 colonies per 105 viable transplanted cells vs. 10.9 ± 2.1 colonies per 105 viable 
transplanted cells in the unsorted control, P < 0.0001; Figure 19G). This represents 
approximately 12-fold enrichment of spermatogonial colonizing activity in the human-to–nude 
mouse xenotransplant assay. 
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Figure 19. The EPCAM dim /CD49e negative/HLA-ABC negative fraction of MOLT-4–spiked 
human testis cell suspension is enriched for human spermatogonia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.4 Tumor formation of FACS sorted cells following transplantation into the testes of 
nude mice. 
To determine whether MOLT-4 cells had been successfully removed from the sorted population 
of spermatogonia, tumor formation was assessed following transplantation of the sorted fractions 
into the testes of nude mice. In a prior sensitivity analysis, it was demonstrated that 
transplantation of as few as 10 MOLT-4 cells into the testes of nude mice could induce tumor 
formation [159]. 
 (A) Human testicular cell suspensions were spiked with 10% MOLT-4 cells and then FACS sorted using 
EPCAM-PE, HLA-ABC-APC and CD49e-APC antibodies. (B) Fraction III in A was further analyzed with side 
scatter, as described in Figure 11, to identify the SSC fraction, EPCAM dim/side scatter high (green, Fraction IIIa). 
Only cells that (A) primarily fell within fraction III and (B) secondarily fell within fraction IIIa were collected. 
(C–F) Immunocytochemistry was performed to assess relative SALL4 expression in unsorted and sorted fractions. 
We focused specifically on fractions II and IIIa (green), because this is where we expected to find MOLT-4 
leukemia cells and human spermatogonia, respectively, based on data in Figures 13 and 18. Scale bar: 50 μm (C–
E). Bars in F indicate the mean percentage of SALL4–positive cells (SALL4–positive cells/total cells) in each 
fraction. Error bars in F represent SEM from 6 replicate sorting experiments. (G) The human-to–nude mouse 
xenotransplantation assay was used to assess spermatogonial colonizing activity in unsorted (unspiked) and sorted 
(spiked) testis cell fractions (I, IIIa, and IV), as described in Figure ?. Bars indicate the mean number of colonies 
per 106 viable cells in each fraction. Error bars represent SEM from 6 replicate sorting experiments. *P < 0.001, 
compared with unsorted cells. A typical colony of human spermatogonia in recipient mouse seminiferous tubules 
is shown in the inset. Scale bar: 50 μm. Reprinted with permission from Dovey SL and Valli H et al., J Clin 
Invest. 2013 Apr 1;123(4):1833-43, Copyright (2014). 
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 Figure 20. EPCAM–/CD49e+/HLA-ABC+ cells form testicular tumors following transplantation into 
nude mice, but EPCAMdim/CD49e–/HLA-ABC– cells do not form tumors. 
 
 
 
 
Following sorting of the spiked testicular cell population, the EPCAMdim/CD49e–/HLA-
ABC– (putative SSCs, fraction IIIa) and EPCAM–/CD49e+/HLA-ABC+-sorted (putative MOLT-
4 cells, fraction II) fractions (Figure 19A and B) were transplanted into the seminiferous tubules 
of nude mice. Uncontaminated testicular cells, a pure population of MOLT-4 cells, and unsorted 
spiked cells were transplanted in the same manner to serve as negative and positive controls, 
respectively. When a pure population of MOLT-4 cells was transplanted into the seminiferous 
tubules, tumor formation was observed 18% of the time (Table 4). The unsorted spiked 
population of cells produced tumors in 41% of testes transplanted (Figure 20A and Table 4). The 
EPCAM–/CD49e+/HLA-ABC+ fraction produced tumors in 23% of transplanted testes 
(Figure 20B and Table 4), whereas tumors were never observed in the EPCAMdim/CD49e–/HLA-
ABC– fraction (Figure 20C and Table 4). 
(A and B) Unsorted spiked testicular cells and cells from fraction II (see Figure 19A) produced tumors in 
recipient mouse testes. (C) Cells from fraction IIIa (see Figure 19A and B) that contained human spermatogonia 
colonizing the seminiferous tubule of nude mice (see Figure 19G) did not produce tumors. Reprinted with 
permission from Dovey SL and Valli H et al., J Clin Invest. 2013 Apr 1;123(4):1833-43, Copyright (2014). 
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Table 4. Quantitative assessment of tumor formation in recipient mouse testes 
 Testis number (n) Tumor formation [n(%)] 
Before sort* Intratubular Interstitial Intratubular Interstitial 
Testis cells 29 n/a 0 (0%) n/a 
MOLT-4 cells 28 25 5 (18%) 18 (72%) 
Testis cells + 10% MOLT-4 
cells 32 26 13 (41%) 16 (62%) 
After sort  
EPCAMdim/CD49e-/HLA-
ABC- 25 30 0 (0%) 0 (0%) 
EPCAM-/CD49e+/HLA-ABC+ 22 29 5 (23%) 16 (55%) 
*Unsorted (before sort) and sorted (after sort) cell fractions were transplanted into seminiferous 
tubules or interstitial space of recipient mouse testes. n/a – not applicable.  
 
For additional confirmation that MOLT-4 contamination had been successfully removed from 
the EPCAMdim/CD49e–/HLA-ABC– fraction, interstitial testicular transplants were performed. 
Earlier work with MOLT-4 testicular transplantation suggested that tumor formation may be 
more efficient when cells are introduced into the interstitial space, thus increasing the sensitivity 
of the tumor bioassay. The same cell fractions were transplanted into the interstitial space of the 
testes in nude mice. Approximately 5,000 MOLT-4 cells were transplanted per testis in the 
control arms of this cancer cell–spiking experiment (i.e., 5,000 MOLT-4 cells or 50,000 unsorted 
testis cells spiked with 10% MOLT-4 cells). Unlike in the intratubular transplantation 
experiments above, tumor analysis was not performed until 16 weeks following transplantation, 
or sooner if palpable tumors were present, to maximize the sensitivity of the tumor bioassay. 
With the interstitial transplants, 72% of testes transplanted with pure MOLT-4 cells developed 
tumors, as did 62% of testes transplanted with an unsorted spiked suspension of cells (Table 4). 
Following sorting, tumor formation was observed in 55% of testes transplanted with the 
EPCAM–/CD49e+/HLA-ABC+ (putative MOLT-4) fraction, whereas there was no tumor 
formation in any of the testes transplanted with the EPCAMdim/CD49e–/HLA-ABC– (putative 
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SSC) fraction. Pathological analyses of the samples (by C.A. Castro) indicated that they are 
consistent with lymphocytic tumoral growth, with characteristic malignant invasion through the 
tunica albuginea and into abdominal organs. Furthermore, immunohistochemical analyses of 
testicular tumors with a human-specific antibody directed against the nuclear mitosis apparatus 
protein (NuMA) demonstrated that the tumors are of human origin (Figure 21). Thus, a 
multiparameter sort strategy effectively segregated undifferentiated spermatogonia from MOLT-
4 leukemia cells. FACS reanalysis of the EPCAMdim/CD49e–/HLA-ABC– fraction demonstrated 
a purity range of 98.8%–99.8%. 
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Figure 21. Testicular tumors observed after transplantation of the EPCAM-/CD49e+/HLA-ABC+ 
fraction following FACS are of human origin. 
 
 
 
 
 
 
 
 
 
To demonstrate that the multiparameter sorting strategy could be generalized to other  
cancer cell lines, I contaminated human testis cell suspensions with TF-1a human leukemia cells 
[272]. TF-1a cells did not efficiently make solid tumors following xenotransplantation to nude 
mouse testes, so I labeled them with ubiquitin-C-GFP to enable tracking and assess 
contamination of sorted fractions (Figure 22). TF-1a cells did not express HLA-ABC to the same 
degree as the MOLT-4 cell line, so an alternate epitope, CD45, was used instead. A 
multiparameter FACS procedure was performed using EPCAM-APC (spermatogonial marker), 
CD49e-PE (TF-1a marker), and CD45-PE (TF-1a marker) on a human testicular cell suspension 
spiked with TF-1a cells, as described for the MOLT-4 line above (Figure 22). A purity check 
indicated that the putative spermatogonial fraction (IIIa) was 99.4% pure (Figure 22C and E). 
This fraction contained SALL4 positive spermatogonia (Figure 22H) but was devoid of 
GFP+ TF-1a cells (Figure 22F and H). 
(A, D, G) Cross-section of a nude mouse testis showing normal morphology. (A) Stained with H&E, (D) staining 
with the human-specific nuclear mitotic apparatus protein (NuMA) and (G) is an IgG isotype control. (B, E and 
H) MOLT-4 leukemic cell suspension. (B) MOLT-4 cells stained with H&E, (E) NuMA antibody, and (H) with 
an IgG isotype control. NuMA is expressed by a variety of human malignancies, including MOLT-4 leukemic 
cells, as demonstrated in (E) but not expressed by mouse testicular cells (B). (C, F and I) Testis from nude 
mouse demonstrating gross tumor formation following transplantation of EPCAM-/CD49e+/HLA-ABC+ cells. 
Disruption of the normal morphology of the seminiferous tubules by the MOLT-4 leukemic cells can be 
visualized in (C) (bottom right), and these cells stain positively for NuMA (F). (I) MOLT-4-derived tumor 
stained with an IgG isotype control. Scale bar = 100µm. Reprinted with permission from Dovey SL and Valli H 
et al., J Clin Invest. 2013 Apr 1;123(4):1833-43, Copyright (2014). 
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Figure 22. Separation of TF-1a–GFP cells and human spermatogonia from a contaminated human 
testis cell suspension using a multi-parameter FACS approach.  
 
 
 
 
 
 (A and D) Human testicular cell suspensions were “spiked” with TF-1a-GFP cells (15.6%) and then FACS was 
performed using EPCAM-APC, CD49e-PE and CD45-PE. (B) Fraction III in (A) was further analyzed with side 
scatter, as previously described, to identify the spermatogonial fraction, EPCAM dim/side scatter high (green, 
fraction IIIA). (C and E) Purity check indicated that the EPCAM dim/side scatter high (green, fraction IIIA) 
fraction was 99.4% pure and contained no GFP positive cells (E and F), representing the TF-1a leukemic  
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4.4 DISCUSSION 
SSCs may have application for preserving and restoring spermatogenesis in men who are 
rendered infertile due to chemotherapy or radiation treatment for cancer or other conditions. A 
boy or man could theoretically cryopreserve testicular tissue or cells (containing SSCs) before 
the gonadotoxic therapy and have these cells reintroduced into his testis after he is cured of his 
primary disease. For a cancer survivor, this approach has the inherent and unacceptable risk of 
reintroducing malignant cells. I created this scenario in this study by contaminating human testis 
cell suspensions with MOLT-4 leukemia cells. I then used a multiparameter sorting approach to 
prove that it is feasible to isolate and enrich SSCs from a heterogeneous human testis cell 
suspension and also remove malignant contamination.  
EPCAM, our selected spermatogonial marker, is a calcium-independent adhesion 
molecule that is expressed by murine embryonic stem cells, primordial germ cells of both sexes, 
and spermatogonia in adult mice [274]. Furthermore, Ryu and colleagues demonstrated that 
EPCAM could be used as a cell surface marker to isolate and enrich transplantable SSCs in the 
rat [29]. The majority of SALL4 positive spermatogonia were recovered in the 
EPCAMdim fraction of human testis cells, and xenotransplant colonizing activity in this fraction 
 cells. (G-I) Unsorted and sorted cell fractions were evaluated by immunocytochemistry for SALL4 (human 
spermatogonia) and GFP (TF-1a-GFP). We focused on fractions II (red) and IIIA (green) because these were 
expected to contain TF-1a leukemic cells and human spermatogonia, respectively. The EPCAMdim/CD49e-
/CD45-fraction (IIIA) contained SALL4 positive spermatogonia, but not GFP positive TF-1a cells (H). The 
EPCAM-/CD49e+/CD49+fraction (II) contained GFP positive TF-1a cells, but not SALL4 positive 
spermatogonia (I). Scale bars = 100 µm. Reprinted with permission from Dovey SL and Valli H et al., J Clin 
Invest. 2013 Apr 1;123(4):1833-43, Copyright (2014). 
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was enriched nearly 6 fold compared with that in unsorted controls (Figure 13). It is important to 
confirm experimentally that rodent spermatogonial markers are conserved in humans. CD29 (β1-
integrin), for example, is a marker of rodent SSCs that does not appear to be conserved in 
humans [181] (Valli and Orwig, data not shown). Others have reported that SSEA4 [112] and 
GPR125 [143] are cell surface markers of human spermatogonia. I did not observe 
immunoreactivity for either marker with human testis cell suspensions in this study. These 
disparate results might be attributed to differences in cell processing (i.e., trypsin concentration) 
that affect cell surface antigens or the use of different antibodies. 
I further refined our sorting strategy by adding 2 MOLT-4 leukemia cell markers (CD49e 
and HLA-ABC) to the staining cocktail that was then used to analyze and fractionate MOLT-4–
contaminated human testis cell suspensions. The putative spermatogonial fraction 
(EPCAMdim/CD49e–/HLA-ABC–) was enriched 12-fold for colonizing activity in the human-to-
nude mouse xenotransplant assay. This fraction never produced a tumor following 
transplantation into seminiferous tubules or into the testicular interstitial space. In contrast, the 
putative MOLT-4 leukemia cell fraction was depleted of SALL4 positive spermatogonia and 
produced tumors in seminiferous tubules as well as in the testicular interstitial space. Similar 
results were obtained by Hou and colleagues, who used EPCAM in combination with leukemia 
markers to remove malignant contamination in a rat model of Roser’s T cell leukemia [185] and 
concluded that a multiparameter sorting strategy that included both spermatogonial and leukemia 
markers was required to eliminate malignant contamination and leukemia transmission. 
I then replicated this finding using a different human leukemic cell line, TF-1a, to 
demonstrate that the multiparameter FACS strategy to remove malignant cells from therapeutic 
spermatogonia can be applied across different malignancies (Figure 22). It is important to note, 
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however, that I needed to use different cell surface antigens when sorting the TF-1a cells from 
spermatogonia, as their cell surface phenotype was somewhat different than that of MOLT-4 
cells. Through a series of similar experiments, it may be possible to identify a broad panel of 
markers that can be used in a generalized approach to remove a variety of malignant cell types 
from human testis cell suspensions. 
Two prior studies have attempted to separate spermatogonia from cancer cells in a human 
model. In 2006, Fujita and colleagues demonstrated via flow cytometry that several human 
leukemic cell lines uniformly expressed cell surface antigens MHC class I and CD45 [263]. They 
then performed FACS on human testicular cells and demonstrated that the MHC class I–/CD45–
 fraction contained germ cells (assessed qualitatively by RT-PCR for germ cell markers), 
suggesting that these cell surface antigens could be used to sort leukemic cells away from germ 
cells. However, the authors of that study did not report sorting and transplantation of 
contaminated human testis cell suspensions, as they had previously reported for mice [262]. 
Geens and coworkers did contaminate human testis cell suspensions with B cell acute 
lymphoblastic leukemic cells but were not able to remove the malignant contamination using 
FACS-based selection for HLA-ABC [264]. 
Our study adds significantly to the current literature by demonstrating that a 
multiparameter sorting strategy can enrich spermatogonia and eliminate cancer contamination 
from a human testis cell suspension. These conclusions are supported by quantitative in vitro and 
in vivo assessments, including transplant of selected fractions into the seminiferous tubules of 
recipient mice. This human-to-nude mouse xenotransplant assay is most relevant to the cancer 
survivor paradigm in which the ultimate objective will be to transplant a patient’s cells back into 
the seminiferous tubules of his testes to reinitiate spermatogenesis. However, these bioassays 
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require a large number of cells and time. Ultimately, it will be necessary to identify specific, 
sensitive markers of SSCs and cancers cells so that assessment of stem cell activity and 
malignant contamination can be conducted quickly and with a relatively smaller portion of the 
patient’s tissue. Molecular readouts, such as PCR, are rapid and likely have the best sensitivity to 
detect occult tumor cells, and, indeed, evaluation of minimal residual disease (MRD) with PCR 
is now being investigated as a more precise means to screen tissue for transplantation [275]. 
Alarmingly, assessment of MRD in ovarian tissue destined for autotransplantation in patients 
with leukemia identified malignant contamination in the majority of samples, even after a 
negative histology and immunohistochemistry examination [275, 276]. 
One current limitation to performing MRD screening routinely prior to transplantation is 
the need to identify a PCR target unique to the cancer of interest. However, identifying a 
distinctive PCR target for MRD screening is just half of the equation. What is the clinical 
significance of very-low-level contamination detected only by PCR for a given malignancy? 
How likely is this to result in clinical relapse if the tissue is transplanted? Courbiere and 
colleagues discussed this issue eloquently in an editorial describing a patient with chronic 
myeloid leukemia who underwent ovarian tissue harvesting in which autotransplantation of the 
tissue was debated after histology evaluation was negative but PCR demonstrated a small 
number of BCR-ABL transcripts in the cortical tissue (0.001%) [277]. Considering that the 
survival and engraftment of tumor cells will depend on the type of cancer and number infused, it 
was felt clinically that the likelihood of inducing relapse was low if transplantation was 
performed, but the absolute risk is virtually impossible to quantify. 
The findings in our study parallel this clinical dilemma, in that the FACS reanalysis 
purity check demonstrated that the EPCAMdim/CD49e–/HLA-ABC– fraction was 98.8%–99.8% 
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pure. Furthermore, this fraction did not produce tumors in 55 transplanted testes (intratubular and 
interstitial). Do these results indicate that approximately 99% purity should be considered safe 
for autologous transplantation? In the bone marrow transplant field, “purging” malignant cells 
from HSC samples prior to autologous transplant has been studied extensively for over 2 
decades, as autologous bone marrow transplant is considered standard treatment for patients with 
various malignancies [278]. Overall, there is limited convincing evidence that transfusing a small 
number of cancer cells in HSC grafts causes relapse or that purging HSC grafts decreases rates of 
relapse, and results from phase II and III clinical trials have been mixed [278, 279]. Clearly, HSC 
transplantation and spermatogonial and/or ovarian transplantation are not clinically equivalent, 
considering that HSC transplantation is required to treat or cure life-threatening conditions, 
whereas fertility preservation procedures are elective. Nonetheless, HSC graft purging studies do 
highlight the point that in vitro measures of decontamination efficiency, such as PCR, may not 
always be appropriate surrogates of clinical outcome. Short of performing a clinical trial, 
biological readouts, such as xenotransplantation, may be the most relevant end points to assess 
the adequacy of decontamination. Indeed, as our ability to detect MRD through molecular 
methods improves, it is likely that clinicians will face this challenging scenario on a more 
frequent basis. Thus, it will be important to not only improve MRD screening techniques, but 
also to correlate MRD screening results with xenotransplantation studies, so that the clinical risk 
of inducing a relapse following transplantation of tissue with trace MRD can be estimated. 
Progress in culturing human SSCs has been reported by several laboratories in the past 
few years [26, 94, 95, 143, 280] and may provide an alternative approach for removing 
malignant contamination. In theory, it may be possible to amplify human SSCs clonally from 
individual cells or from small enriched fractions of testis cells and thereby alleviate malignant 
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contamination. This will require continued progress to establish robust culture conditions in 
which human SSCs survive and can be expanded over several passages to produce a sufficient 
number of stem cells for therapeutic application. 
I have demonstrated that it is feasible to enrich SSCs and remove malignant 
contamination from a heterogeneous human testis cell suspension. As the panels of 
spermatogonial and cancer markers expand, it will be important to test sorting strategies on 
primary human cancers, which are likely to be more heterogeneous than the MOLT-4 and TF-1a 
leukemia lines used in this study. In addition, it will be important to develop methods to rapidly 
screen cell populations for malignant contamination and establish criteria for assessing safety 
prior to transplant. Continued work in this field is important, because clinics are already 
cryopreserving testicular tissue and ovarian tissue for patients with cancer in anticipation that 
this tissue can be used in the future to restore fertility. Autologous transplantation of tissue or 
cells is among the techniques being considered for both sexes, so risk of reintroducing cancer is 
of paramount concern.  
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5.0  SUMMARY AND CONCLUSIONS 
Spermatogonial stem cells are adult tissue stem cells that balance self-renewal and differentiation 
to support spermatogenesis throughout a male’s life. These cells may also one day be used in 
clinics to treat some cases of male infertility. The SSCs can only be definitively identified by 
their biological potential to produce and maintain spermatogenesis after transplantation. This 
assay was first described by Brinster and colleagues [122, 123] and is widely used to analyze 
SSC activity in any given rodent testis cell population. Obviously, human-to-human transplants 
as a routine bioassay are not possible and there is a lack of experimental tools to analyze SSCs in 
human testis tissues or cell suspensions.  
For grown men and pubertal boys, the effective and well established method to preserve 
their fertility while undergoing cancer treatment or bone marrow transplant is to cryopreserve a 
semen sample (Figure 15, top). Unfortunately, many post-pubertal patients (especially 
adolescence boys) do not preserve a semen sample and this is not an option for prepubertal boys 
who do not yet make sperm. However, these boys do have spermatogonial stem cells in their 
testis that will initiate spermatogenesis at puberty. There are several experimental stem cell based 
options in the research pipeline that may be available for the patients in the future (Figure 15). 
Several centers around the world are already cryopreserving testicular biopsies from prepubertal 
patients in hopes that when these patients are ready to have kids, the techniques to restore their 
fertility are available in clinics [91, 93-95, 100, 222-224].  
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Feasibility and safety studies using human tissues are important to ensure responsible 
translation of stem cell reproductive technologies to the clinic. Techniques currently under 
investigation involve using either a cell suspension or intact pieces of tissues and it is uncertain 
which technologies will progress to clinical application. Therefore, it is important to optimize 
tissue processing and cryopreservation to maximize patient access to downstream applications. 
Additionally, the biopsies taken from prepubertal patient may have malignant contamination 
since they are obtained prior to the initiation of chemotherapy. Therefore, methods are needed to 
eliminate the risk of reintroducing cancers when using these cells. 
To begin addressing these issues, I had to develop experimental tools to analyze and 
quantify human SSCs. A modification of the mouse SSC transplant method has been used in 
humans and is becoming the gold standard for quantifying human SSC-like activity [94, 95, 104, 
106, 112, 118-120]. In our lab, we have generated a rabbit anti-primate antibody that recognizes 
primate cells (including human) in mouse testis [53, 114, 118, 120, 159] (Figures 4 and 5). The 
human-to-nude mouse xenotransplantation assay has 2 month delay from transplant to analysis. 
Therefore, I also developed a quick read out assay that involves staining for human 
spermatogonia markers by immunocytochemistry. 
SALL4, PLZF, UTF1, ENO2 and UCHL1 were identified as markers of undifferentiated 
human spermatogonia. All of these markers are expressed by cells on the basement membrane of 
seminiferous tubules but do not co-express the differentiation marker KIT (Figure 6). Therefore, 
all of the markers can be used in immunocytochemistry to identify human stem and progenitor 
spermatogonia.  
Next, I used ICC and human-to-nude mouse xenotransplantation to identify cell surface 
markers that can be used to isolate and enrich human spermatogonia. I demonstrated that cell 
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surface markers THY1, EPCAM and ITGA6 can all be used to enrich human SSCs with FACS 
sorting (Figures 11-13). Out of the three markers, only ITGA6 was amenable to MACS sorting 
(Figure 14), which is a higher throughput method than FACS.  
 It is not known which fertility restoration technique will be translated to the clinics in the 
future, therefore, optimization of testicular tissue cryopreservation methods is extremely 
important. The preferred cryopreservation technique should maximize the access to downstream 
technologies to restore fertility for the patients. Great progress has been made in SSC 
transplantation technique (Figure 15, blue boxes). Homologous species SSC transplantation has 
now been reported in mice, rats, pigs, goats, bulls, sheep, dogs and monkeys, including the 
production of donor-derived progeny in mice, rats, goats and sheep [70, 73-85, 90]. In contrast to 
SSC transplantation, which involves disaggregation of SSCs from their cognate niches, testicular 
tissue grafting and testicular tissue organ culture maintain the integrity of the stem cell/niche 
unit. Testicular tissues obtained from newborn mice, pigs and goats could produce complete 
spermatogenesis when grafted under the skin of nude mice [207].  In mice, the resulting sperm 
were used to fertilize eggs by ICSI and gave rise to live offspring [208]. Xenografting with 
prepubertal rhesus macaque also successfully produced complete spermatogenesis with 
fertilization competent sperm [281]. Survival and spermatogenesis from adult testicular tissue 
grafts have been less successful than immature grafts [242]. Human tissue grafting into nude 
mice has been less successful as no one has reported the production of haploid gametes or sperm 
[210, 211, 282-285]. The most advanced stage of germ cell development reported from human 
testicular tissue grafts to date has been pachytene spermatocytes [211, 212, 232]. The results of 
the monkey studies suggest that autologous transplantation may be an option if suitable 
cryopreservation conditions are developed. Similar to SSC transplantation, autologous grafting 
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will be problematic in cases where malignant contamination of the testicular tissue is suspected.  
Xenografting of human testicular tissue into animals could circumvent this problem, but is 
associated with additional concerns about xenobiotics and has been unsuccessful to date.   
Sato and colleagues [213, 214] reported production of sperm and live offspring from an 
organ culture method (Figure 15, yellow boxes). If these results in mice can be translated to 
humans, testicular organ culture would circumvent the need to put tissues or cells back into the 
patient and may be a safe option for patients with malignancies that contaminate the testes.   
 I validated and compared methods for cryopreserving human testicular cells or tissues 
and subsequent recovery of stem and progenitor spermatogonia in order to optimize processing 
of patient tissues. I found that slow-freezing small (3-5mm3) or large (6-10 mm3) tissue pieces is 
the optimal method to preserve SSC colonizing activity (Figure 17). In our hands, recovery of 
human spermatogonia after tissue vitrification was not as effective as slow-freezing.  
Nonetheless, this method was equal to or slightly better than freezing a cell suspension and 
therefore could be used if no slow-freezing machine is available.  Freezing intact tissues retains 
the options for either tissue based or cell based therapies in the future [196]. 
The biopsies obtained from the prepubertal patients are taken prior to their cancer 
treatment and therefore have a chance of malignant contamination. It has been shown that 20% 
of boys with acute lymphocytic leukemia have cancer cells in a testicular biopsy taken prior to 
the initiation of chemotherapy [269]. That is an important concern because prior to translating 
the SSC transplantation technique to the clinics, we have to be sure that we do not reinitiate 
cancer in these survivors. Here, I provided proof in principle that by combining positive selection 
with human spermatogonia marker EPCAM with negative selection for MOLT-4 leukemia cell 
like markers HLA-ABC and CD49e in FACS, it is possible to remove the malignant 
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contamination from the potentially therapeutic SSCs. In this case, I used a fairly homogenous 
cancer cell line and therefore, these experiments have to be replicated using primary human 
cancers, which are more heterogeneous than a cell line. This is necessary to make sure no 
malignant contamination remains in the patient samples. Development of cell culture or organ 
culture methods to expand transplantable stem cells or produce sperm could also circumvent the 
concerns about transplanting malignant cells or tissues (Figure 15, bottom, blue and yellow 
boxes). 
Stem cell technologies for treating male infertility have the potential to impact the clinic 
in the near future and therefore it is important to establish criteria to monitor progress and 
analyze the outcomes. Although it is not popular in the current era that prioritizes the highest 
impact, innovative and novel science; descriptive studies of human germ lineage development 
are essential to guide experimental design and enable accurate interpretation of results of human 
stem cell studies. This knowledge is critical, as I believe it is reasonable to expect that SSCs or 
other stem cells will be used to preserve and restore male fertility in the coming decades.     
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